var title_f26_5_26704="RIDTs during periods of high influenza activity";
var content_f26_5_26704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Algorithm to assist in the interpretation of rapid influenza diagnostic test (RIDT) results and clinical decision-making during periods when influenza viruses are circulating in the community*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RIDT: rapid influenza diagnostic test.",
"     <br>",
"      * During periods when influenza activity is high and influenza viruses are circulating among persons in the community (see &Delta; below), the positive predictive value of a test result is high (that is, the chance that a positive result indicates that the patient has influenza is high), and the negative predictive value of a test result is low (the chance that a negative result is a true negative is low) due to low sensitivity of RIDTs to detect influenza virus in respiratory specimens compared to reverse-transcriptase polymerase chain reaction (RT-PCR) or viral culture: false negative results are common.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Influenza virus infection may include seasonal influenza A (H3N2), 2009 H1N1, influenza B, or rarely, a novel influenza A virus infection. The interpretation of RIDTs will, in part, depend on the test used - some will detect influenza A, some will detect influenza B and some will detect both A and B viruses. If tests for both influenza A and influenza B are positive, refer specimen to a public health laboratory for resolution, as dual infections are uncommon.",
"       <br>",
"        &Delta; Consult local or state health departments or other sources (eg, virology testing at a local hospital) for local activity on other respiratory pathogens associated with acute respiratory illness. Empiric antibiotic coverage should include coverage for",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        (including methicillin-resistant",
"        <em>",
"         S. aureus",
"        </em>",
"        ), Group A streptococci, and others, especially for hospitalized adult patients per the Infectious Diseases Society of America/American Thoracic Society community-acquired pneumonia (CAP) guidelines.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     United States Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests.&nbsp;",
"     <a href=\"file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm\" target=\"_blank\">",
"      file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm",
"     </a>",
"     (Accessed on April 4, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26704=[""].join("\n");
var outline_f26_5_26704=null;
var title_f26_5_26705="Emergency pericardiocentesis parasternal approach";
var content_f26_5_26705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Emergency pericardiocentesis parasternal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 499px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHzAgkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorm9e8Yadpc7WsO6+1Af8u8GCV/326L+PPtXE6pd6r4gY/2rcGC0PSytWKoR/tt1b9BWNStGHqbU6Mp+h2ms+NdI06RoYpXvrsceRaL5hB9z0H4mubuvFniK+JFpBaaXEe7/v5f6L/OqdnZRQRLHBEscY6KowKuxw+1cssROW2h1Rw8I76lAy6zNk3Ouai7Hr5bLEPwCgYqMR3oORq2r59ftsh/TOK2RCPSlMIx0rLml3NOWPYzbbU/ENi+611Q3Sd4b6MOD/wJcMK6LS/HVszrDrtu+mTHgSE74G/4GPu/8Cx9ayzEAaikgVgQQCD1B71pCvOJEqMJdD0mKRJo1kidXjYZVlOQR7GnV5NBps2nyGTRr2509yd2yJsxE+8Z+U1t2HjLULH5NfshNEP+XqyBJ/4FGefxBP0rphiIy30OaeHlHbU76iqml6lZ6rZrdadcR3EDcBkPQ+hHUH2NW66Dn2CiiigAooooAKKKKACiiigAoqJ5kDbARu7+1Kr+9K47ElFAOaKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKwfE/ia00KJUKm5v5P8AVWsZG5vc/wB1fc0m0ldjScnZGpqeoWml2Ul3fzpBboMs7n9B6n2Fec6v4l1TXg8VoX03TWOAV/18q+5/gB9Bz71mXT3mr3i3mtSLNMpzFCv+qg9lHc/7R5q3Gua4auIctIndSw6jrLcgsbOG1jEdvGqJ7dz6k960YovWlii71ZjTmuc6B0cQGKtJGMUxcCplYVaIYgjFIyinlhUbNTEQOOahcY5qw9REZqGWiNWpXRZF5pjqQcikSTnBoHYz0F5ouoNf6M4WVv8AXW7cR3A9/RvRv6V6J4c1y116wFxanbIp2zQt9+F+6n/HvXHSIJFrKlhubG+F/pUv2e+Xgn+CZR/A47j36jtW1Ks4aPYwq0VPVbnrdFct4a8aafq5+z3RFjqK8PbzNgE/7DdGH6+1dTXfGSkro4JRcXZhRRRTEFFFFABWbrerQ6XFGG+e4mOyGIdXP+A7mpNa1O30jTpb28fZDGOcdWPZQO5PpXnUFxc3t7JqmpLtuphtji6/Z4uyD37k+v0rGrVUF5m1Klzu/Q6uC4fJZ2yx5J9TWjBd56muYgmY96vRSnNc0aljolTOoilDCpw2awba5IHJrRhnBA5rqjUTOaULF6io0fNSVqZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFMmljgieWZ1jjQFmdjgKB3JrzTxD4puNe8y10iR7bSvutcjKyXHqE/ur79TUTqKCuy6dNzdka/ibxkRJNp/h/bLdoSkt0wzFAe+P7zD06Dv6VyFrbLC0kjO81xKd0s8p3PIfUmnQRR28KRQoEjUYCimzXCQIGfJJIVVUEsxPQADkmvPqVJVGehCnGmi2oFTRkA0WujaldxhriUWQbpHGBJIB7sflB9gG+tX4fCecE6jqCt/e3Rn9NmP0q1hpsh4mCYkTVMDWfrVtqehRx3AWG/sQcSyf6p4v9ojkEep4xnnAyals72O5Z49rw3EYy8Mow6+/oR7gke9ROlKGrRcasZ7Mu7qXdTKSouWShjRmo80uaLiFNNNBNJSGBGaryrtORUzuqDLHFKwDLQBBHJTpcMtQSkRsM96lQ5FAzE1XTopcu8KSA9QwzTNNudT01QNI1S4giH/LCX99GPYBuR+BFbroCKy7q3MT706dxTUnHYTSejNiy8c6vDhdQ0y2uh/ftpTGf++WyM/jWxF8QNJ4+2Q6hZ+pltyyj8U3CuPjXcAcVZQADmtY4maMZYeDO4h8Y+HZU3LrViB6PKFP5HBqneePvD1uD5V6btx/BbRtJn8cY/WuIuVhZstGhPuoJqS3tN+1pAFjHIQCr+tS7E/VY9y5f3114g1CO9vYjBZQc2tqxyQ3/AD0ftu7AdvrzSj5mprt2FTW6Z5rCUnJ3ZvGKirIt268Crka1FAnFW1XFVFEtjkYip458HrVVmwKjL4NXzWI5bm7b3WeCavxSg965aO4KmtG1u+nNbQqmM6R0AORRVOCfcBzVtWBFdKdzmasLRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNkkSKNnkdURRksxwAPc1z8vjHSjKYrB5tSkBwfsUZkQH0MnCA+26gDoqK5SXVfEN4SLLT7PT4e0t5KZX/AO+EwP8Ax+su8jlcn+2fE1247xWrC3X8DGA35saAO6ubmC1TfczRQqeMyOFH61kXHi3QIM51W1kI4IgbziD6YTJrh5bjwjpz+c1nHLL/AM97gBm/77bJ/Wo28facPlsII5QOB5UbTf8AoINF7Ba5T8ReI7zxNdvGdO1RNIjb93b/AGV1M5H8bkgDHov51CragVHl6FqTAdMCIfzcVck8aapMP9H0+cD/AK5Kn/oRFQnxXrp5+yzL9Xj/AKMa5pQpSd5P8TpjOqlaK/AqXE+oQIXm0PU0Qck4iOPyc1r+Crc35/taWN13kx2yOOUUHDNj1JBH0HuawtY8Wao1sY7uGYq52hVZCT+Ga73wDGs3hfR5kyB9mQMD1DAYYH33A1VOnTT5ok1KlRq0joLa2AA4q8lvjsKmhj2Lz1qStzAg+zRtG6SIrIwKsrDIIPavMpdJLJd21s+2902eSG3lJyVHDIp9QUZAfXr1xXqhIAJJwB3rgvAU8etDxBqa8282qSFHPRo1ijVW/JaGr6ME7alPT7kXljb3KqVEsavtPVcjOD7ipyQBkkAVi+EJvN8OQTtkLI8sig/3TIxX9CK0VJmfLHCjtXlSVpNHqRd0mWVIYAg8U2WRYkLN+XrTGuIk4Bz7LWNdXrT3HyDCLwMn9aOV9htmmjNO4BPvgdqsyMsUZY8AVm2vnCMNuwW54FV9SZgY0Zid2Tyf8+tX7FpXYrmjB+8ffIff/wCtVvI9ax7VVfcoOWUDNWBCKpULq9xoJJEa4yzKPm2jJ96sFdp4rBhgRvOjxh8kZPXOa1YXkeIMrnPcHnB7ipVFvZgmW1OaHjDDBFQrOV/1i/iKso6uuVIIqJQcdx3KjW+37oqBoJi2FH41q8UVIyhDZqpDSfM3vUk7BF9KmkbArIu5jLLsU/WgCaFvMc46Vp2w6VQtVCqBV+JgtCEzRjwBTmkAFUTPgdahe4z3q+YjlLkktR781U84HvQZh61LZSiWt3vUsUpU9azvOzViNsjNCY2jes7rpzWxbz5A5rj4ptp61rWV2DjmumlVOapSOmUgjilqjbT5xzV1WDDiuxO5xtWFooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqOrarY6TB5uoXCQqfuqeXc+iqOWPsATXNT6prWtZFjG2j2PeaUK1w49lOVj+p3H2FAHR6vrOn6PEr6jdRw7zhE6vIfRVGWY+wBrCOt6zqbMNMsU0+1I4uL35pD7iIHC/8CbPqvasa4u9D0BpLqVxcXzDD3E0hdz7F25x7Diq0cnifxN8un2xsbBv+Xi5BjUj1VPvN+gPrQBZv7PTEYS+IL6bV7gHIW4YNGp9oxhB9QufeqZ8Y+bMbTw/YSXMq/Lst4jIV+uOF/HFb+mfD3TYl3avNPqsp6iY7IvwRev8AwItXW2dpb2VusFnBFbwL92OJAij6AcUAef2+jeLdWO69e302Fu0rmWQf8AX5f/H6tDwFp1tDJc65qt7cQxgs48wW8agdSSmG/wDHq7maWOCJ5ZnWOJAWZ2OAoHUk15Z4h1mTxRcbVDR6HE2Y42GDdMP42H930HfqazqVFTV2aU6bqOyMafT9I1S+Sex0qC202Fsw7o8y3B/vuzZbb6KT7mtbYAvoKSJfyp0rYFebObm7s9GMVBWRUn+Ws2/u1t4izZJJwqqMliegHvVi/uEijaSRgqKMkmodEiRphqN/G3mf8u8R/wCWa/3j7mpLJrbQpTpl7c3Q3ahNbuqL1EWVOFHv6mum8M61baRFFLcHbo94BOsuMi2dgCc+iN1z2JOeDw+znScfLkH0NZlpd2+iXn9naiVhtJGLWk7nEZB58onoGHOB3GO4NdmGktUceJi3ZnqkMsc0SSQuskbjKuhyCPUGllkSGJ5JXVI0G5mY4Cj1JrjrDwhp0iGWxmvNO8z5t2n3Twq2e+0Hafriue8X+G/DukxrceJdf17UG6w2Ut2HeU9gqhQfxyMeorsOMk8X+LpPEcsnhzwgyzNKp+1XpOIoov4ju/u46t36LknIxrzxBHpXhS48PeDImvreGF1vNVcYQFz87rjr94nI4AxjI5qbQPD0+vDyri2j0XQWYONOtyQ8xH8Uz/eY/X26Y57240Wz0iyiFlbRraIpSSIKNrIeuR+dAHl1nqk2n2tlp9/AtvDGixRTqcpIQABu/uk+/HvXR20ZkiDMxO7n2pLLTreS4vNAvVDIo/0cvzvhb7h568fKfdTWZZG58O6mNL1Ji1jIdttM55jbshPoexP07isXSSfMjqo1ru0jVulENrIwHOMD8eKzY1j+VXIBYqg59TitrUYjJZSqn3gMj8Dmsa2WJwPlHzdG7g+tYzep1M3hGKytch+a3c5C/Mpx+GP5GtKyn85Sj8TJ94evuKfd2y3Nu0TcZ6H0PrVv3loF7mVaIlq6yxDETjEg9PRq1toxWJbSvbzNbzjleCPUetX7eYW7BHP+jn7jH+E+h9qiEujBMpapGba7WdR8knDexqSNyH86HnI+dPX3HvUGq6slxvtbNVl7PKfur9PU1iWl5NZXQhuJCyno3rXTLCVYx9pYy9tFysjrNyTJujII/lUDv9nbcHC+oJ61Sup92xbdykz43Mh/h7k04rGo4jXJ6kjJP41zud1ZmtzYt5451DROreuDnFTt0rBsphBceYfu/db2B7/h/jW82CM1yNWdik7mffzbIzjrWdAO56mrOqA8HtVOKYLxnNIZpRuABT2nA71nGcDvTPN3HjJpAXnuD60zzs1DHFNJ0XA96tQ2RU5Y5NADQzGpkRiOakEapTi4FAAkYHWpC+Biq7y471XknPrTAtSXAWlt74iQAGsl3LHiiSf7JGH2NJIxCRxryZHPRRQnroJrTU7/AEmV7h1jT72Mk+g9a6NFCKAKzPDenPp2motyQ13J88zDpu9B7DpWrXqU48q1PMqS5noFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWXr2t2mjQIbgtJcSkrBbRDMkzeij+ZOAO5FAGjNLHDE8szrHEgLM7nAUDqSe1cpdeJLvVR5fhmJfJY4OoXCnZ9Y04L/AFOF9N3Ss6+SfVNlz4mkiS2T549PjOYlPYuT/rGHvhR2GeazL3xLc3lz/Znhy2kuLph0Qcgf3mPRV9z+GaAL0q6ZoLy3l/O13qbL+8nmbdI3sT0Vf9lcAelUYLnXvFyD+yIRbaeTj7VOCsWPVB1f8MD3rZ0PwFEJY7zxJN/aF0MN9nH+oRvoeX+rcewruQABgcAdqAOY8O+C9N0iRLqYNf6iOftVwASh/wBheifhz6k109FFABSOyojO7BVUZJJwAKWvNfFWtt4huJdPsJSNHibbPKh5uXHVFP8AcHc9+nSoqTUFdl06bm7Ih8Say/iWfyYCyaHE2fQ3bA9T/wBMx2HfrVUAselSIgCqqgBQMAAcAVYjiGM15s5ubuz0oRUFZEGNqc1QuZDkgVcvH2ZrA1CV5HitYD+/uG2KR/CP4m/AVBZJptr/AGzqO51zY2zc56SSDt7gfzq3fB0vMlCyB/nUdSPatzTLWKys4reBdsca4FS3FtDPgyj5ugI60ybmRp87C8jwCql8AHritbVDb3Cvb3UccluB86OoYMfTBqJLa3tJNyZeUdNx4WqUJMymWQ5aR+c+nWtYU3uyJu5QtvDttGxOkXOpaUOrCzu3QEn25FUNEEWi+OrttTlmvllVFa6u2DyxBhgPux93IIPtg/w12Vig8rJ6k5rmPG1stvqNhqDKGglH2OcEZGCSUz+JYf8AAq746aHNVprlukdrBvsLwwsfkJyh/pW4bQ6uQt5PusUwfsyrjzGH99s8jOPlGB656VxPh66a9gbSbly11bRiS2lPJliHHJ/vLkA+oIPXNb+mzC5ja2uWlVc4cRyMhP4gg1ZymT4gjV42vrJ902kSuSwzh4QcSqD32kZ+qkdSav6ra23ibQSrBXZk/MVqySRS3CR6Xar9jtEMckgXbGMcCNBjDY5BxwMY68DmdE/4kWtS6WpP2Ujz7MnvET936qcr9MHvQBneF7yZkm03UG3X1nwWPWWP+F/rxg+4z3puoWzWVwZAMwSNn/dJ7Vo+NNPeKWDXdLj3XFvnfGv/AC1Q/eT8eo9wKLW/s9StYyrZjnQMquMbgRXPVid1GfOrPcqxS79pVtsi/datC3uRIQkgCS+nY/Sse9tn0471y9v/AHj1X6/41DJqtu8GHG4diOufaso3TsapM19Xt4pLZpnZY3iUsJDwAPQ+1cLdeIPPVoW3CDoVAJL/AF9q0bq7F1Eq6hK8ig5WMnAHpnHU1UaOxkP8Sn2NVOoqWq+LzNqWHdd3l8Pl1My3a6mcpZIUh7F+Me1TyaSzDdc3LOw5A3YA/CrwtmijY20hdfTuKouzZ5OfrXLUr1ZfHJv5nqU6NJLlppJempJa6hPYNtYLLH3GMH8/8a6G2u4ruASwk7ehB6g+lcrKPk5xU/hq4H9rtbbsq6Fm54BH+TUwqNbmOKw8XFyirNHUwpnJI4btV21uTar5U2TEPusBnaPQ1ntqdpE5QFmI67VzipF1O3ePKZYe9Dd3c8tGsUjuE3Iyup7g5qudPjyfkFRaEHd55im2N8BffrzWvigu5nLYRg/dFTx2yJ2FWsVDKSDwM0DF+VBUEk6jvUVxJJjAAFUJUkc8MaALclyvrUBud33ajjtC3XJq1FZH0xSArlnenCInrV5bYL1odQo4oAohAvNbPw/046lqsusTKDaWpaC1B/ik6PJ+H3R+NYGrStDp91JGcOkTsPqATXqPhmyj03w/p1pCMLFAg+pxkn8SSfxrpw0Lyu+hz4mfLG3c06KKK7zgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorkda12fUZptO0CbyxGxS6vwARFjqkeeGf1PIX3PFAFzxB4he2uDp2kRLdamRlt2fKtwf4pCO/oo5PsOa5eee00dpbq8uDd6nIv765lIyR1wOyqOyjgfrWdqesWWhWn2LS0ZmLYLDLvJIx9erOT9Sa1vCvgmW5mTU/E43PkPFY5yqnqGk/vN/s9B7noAZelaPqnjCfz5ZJrPSM/68jDy+0ant/tkY9Aeo9J0TRrDRLQ2+mW6wxk7nPJZ2/vMx5Y+5rQooAKKKKACiiuB8Y+JXvJptF0aQrgmO8u1/5ZjvGh/v9if4fr0mc1BXZUIObsiPxfr7atcSaRpUzLZxnbeXUZ+//wBMkP8A6ER9Kyoo44YkihRUjUYVVGABTIIY4IUgt0CRIMKo7CrUERPWvNqVHUd2elCCgrIdEmamf5VpwAUVVu5gqGoLM2/kyxArN0FPPvrq9fs3kRZ7KvUj6n+VN1a6MNtNKOWA+UerHgD86u6VCbOygibqiAMfU9z+dIZvJIEjLMeBUKzvLL8nGOc/4VQaVp544xwg+b61oWIHllu7MT/SuinT11IerHXQ8qzlbvtxn68Vmvcxxx26A5YuBx2yCK09T50+bjPAJ+meayH/AHto0akKeCvsR0rab1JZ0dsNsKD2qLV7GLU9MuLObhZVIDDqp7Ee4PNJp04mt17Oowynsat1re4rHA6Sb0KYWfyNa0x8q2ODxwcd1YH8iRXb21/HqVnFqdmhjb7k8OcmNx95T/Q9wQe9YPjCBrXyNat0zJa/LPj+KE9T/wABOD9N1Msb3+ybwakuW0q7ULdIozs9JAPUd/UZ6kCtE7nBUhyOx6Day3Wo28dtDLHDbsP30mT5m3+6voTz82eOw7jA8Swi6gnk01jLdaXKZI9q58xQB5sanvx6fxIB1Bq1GUt5jE5ElpOOCrcMp9x2Irnfif4vtdA08rC8VvLHGLa1tLfa0hLYAkKr9xFAwo6knoMUyDqdHvINQsY3yr286jkHI571xOuW0vhi8mDxNPo8rlgAMmFmPUeqknPHQ+x4q/Dr7doOmwaNdjz5vJ86Iu2xVXPKseT8vGcA9RXYQ7tTUqxN1LjbFMV2wQk8FlHV+O/OemVBNS0pKzLTdORxLX7XcQdpi9kw+SJWyH/H0qpIQDlFVB6AVJr+kr4d1xIo/ltrhduD/wA9AOD+Kg5+nvUQBI4Un8KIxjDc74S9rG5G8ZlQnuO9Vzbs5wKuncnVSAarX16sUQigG+dugXtXLiKUask09T0MNiJUIO60QsUktvINpJx1Apmo31lvCBWFy/YHgH3qrFb3zoHkZQpYLtBovLJrOZJJtm5gRgdvxrtpYGmo7XPKrZlWnO60MTX01m2h8+IpLaE7S0Q5X61N4C03Ub7UJ7hgYoo027nPc+w9hXYaNai50K4jmGVuAcZ7dhWz4VsEstISJeZAx8wnu3T+QFedUw0fau2x6cMZKWH5Zbsp6aI4P3bAbo2w3HcdatpDa2+pCV0QxT8KSv3X/wDr0/VrbypFuUHBIV/6GkCJdW7QuflYcEdjS9kk7HFsbSTxY++KmVlb7pB+hrDs2Z4ykwxNH8r+/ofxqbaQcjg1fsE9mVc16aVBrPju3jOG+Ye9XYZklHynn0rKVOURjZogUOOtUE4fDCtaqd3Bn5lrMYsZFWVxisxJCpwauwygigB0lVZjxVmXpVSXpQBj61ltOvFHUwuP/HTXruhTC50TT51ORJbxuPxUGvK7hA2QeQeDXc/DS5M/g6yiY5ltS9q/sUYgfpiurCvVo5cUtEzqaKKK7TiCiiigAooooAKKKKACiiigAooooAKKKKACiiqWqxTXNs0EErwb+HkQ4YDuFPY+/agDnNe1abVbifS9LkMNpHmO8vVODnvFGf73UFv4eg56cnrOsQWlrHpmjREICIY44Fyzt2RR3J/+ua1PErtp1mmnabbuBgRokQyWPZR6k/8A1zWv4G8IDRh9v1LbLqsgPQ5S3U9UT1Pq3f6UAM8EeDhpjJqWrqkmqkfIgO5LYHqFPdj3b8Bx17SiigAooooAKKK4Lxt4sfzn0jQZsXXS5uk5EA/uqf7/APL69JnNQV2VCDm7Id418US/aZNG0SQLPjFzdLz5Gf4V/wBv+X16c3ZWyW0CQxDCqPxPufem6ZYx20IWNfcknJJ7knua1IYfUV5tSo6juz0qdNU1ZDYYcnmrartFKqgCmyOFFQURXEm0GsW9mJOM8Vbu5+vNYeo3SwQtI+TjoB1J7AUhkSxm+1aGH/ljb4nkPq3RR/M/hWtMclR/CT+lVtNtnstMd5+bmc75D7nt+A4rRSISqV7qowfSqi0pK4mZDTytdSLbffztyegxxW1pM26yjDH51+VvqOtYMwktL11cEbjuU+tXElVjvjkMMh6kcg/UV0xlZkXsdFlXRlblWGCK525D2UjQvyOqN6j/ABq0t7cR43RLIP70bYP5H/Go7y9t7iAx3MM49DsOQfwq5NSQ3qWreVXKyo5jlwBuHce471eS9lU4lh3j+9Gc/oa5EXEkDKsQlmX12EEVcgvpzj91KPqpqVJok6WS8tpI2SYNsYFWVozgg9ulYPhKOIQajpEz7orWQiORj/BgFSc+xAPuDVtLh9oLkqfQ1haRk+Nr8SG2zIUaMzQ7+PLUZHI7g/lW1Od3YwxGsbmbBp87a3LYjW9QispP+PZd7NFx1RcnAGOmOOo7Vp6R4QsNH1E6l8k12oIM14cpEvUsFGMnjuffNdleeHre/O++kkmlyGDA7AhHIKgdMHkE5PvWPrHhzVzaOdO1i5eVeQkgjG4em4KCD75+vrWjTexnSqQiveWpWsPs974jsbI75lgD3PmXK/NMMbc7SOMlsgcfcyBjBrvFOGBHavNtJmltNSsY7zTzZtZTh7qR5A0khlUor8E5XLDJyfw2103iHxbpmjRN5twrTY+WNTkk/SmlZGdSfPK5S+LAQ21vMMb0liYf99gH9CRXIXepmJ/Kt1DNjk1l67rmoa9NHNJE0Vmsg2ITlmbtn/CktIJFn3zDG7tnP+etclapd2ietgqEoQcp7FmabUJVDSJiJiFG09SelTQWrW0ytLsy6kYHOOnerxBNhKR1XDD8OaivvuI/91h+R4qYxtr1Otx54tFtRutJVXqORWdrEhu4UCD52wVqzZXG2Tae4q74UsludRuJpQCluSgT3PT9K9bCYmKUlLsePWwcnJNdy5poWOGCFfurgfgK27ABJriMeokH4jH9K5+NGtdWktz91Adv0PStu3bF7byZ4kUxt9eory7+9qdMtGkX5Y1kjZHGVYYI9q58RvY3DQyHMZ5RvUV0hFV7u1S6hMcgPqGHUH1FVKNxGFeXAjaN42zdDgKP4x6Gr1vMJkGVKSY+ZG6j/PrWbNaTWEm6VDIv/PVRnj39KsRXMUqrv5x0YHkfjUxk47i2LjrnpUKuY344qRHJHDB/rwagnbjJVh+Gf5VfMmO5s20wlXn7w/WpyM1iWVwFYfMB9a11lUjO4fnXNViovQpFW7tuCyVRjmKSYrZMiYx1qle2gYebGMGsgTHrKGWo3OappIVODwanD5FIZFKMg1r/AAzu/I1nVtNb7syrexj34R/12fnWU/NVba//ALH13TdRJxFHL5M57eU/BJ+h2n8K0oy5ZpmdWPNBo9kooor1DzAooooAKKKKACiiigAooooAKKKKACiiigAoIzRRQBCtrEJ/OKAygYDEdB7VNRRQAUUUUAFFFea+M/FEuqTTaTosuyzU7Lm7Q8ue8aH09W/AVE5qCuy4Qc3ZEvi3xdLfPNpfh5yqAmO4vh27FY/U/wC10HasHTdPjtY1jiXCj/Oal06ySCJI41CqowAO1a0MIX61506jqO7PRhBU1ZDYYdo5qwBilFIzAVBQMcCs+8mxwKmuZgq9axrqfJPrSGiK5lznmqWkQHU74XTjNpAT5Wf436bvoOQKhnEl/drp8BOXGZnH8Cf4npXUWMUcIS3hQLGi7QB7UwZX1bEdqh/2x/Wo9I8yO4kWZgfNUMv4dRV/UbU3FqyL99SGX6iseGZWQLJuGDkEcFTSJe5rX1nHdxbJB7gjqDWFLplzCTtUSL6qcH8jWyl02zHnIx9SnP6Gq82+U5e4k2/3U+Uf40XB2MuFmWYRNHIr9cegq+nynk5oZo4FIVQAevvVZWnuSRbJkDqx4Ao5n3JsWpJVUc8VVkuogcZJPsanj0pmObmZm/2U4H51oW9tDbjEUaqfXHP507vuPlMgRXU3MEUmPV+B+tZGt6bfRzQ3kZjS8i+4obl17qf6Ht+NdfeXS20O8gsxOFUdzXOatdLawSS3L7rh+w7e30q4VJRegpQTVmb/AIf8YWV3aKty/lzp8rq3UEdQak1fxrpenx8yF3P3VAyW+gryj7NJqF8shDRFuAyHaSK6XQPD1t5TSyqWkYnJY5J+pPNdnt18znjhHJ76GB4x1+98UoRbW4t1jxsuSP3iEEEEenIBrF0FVuHMt0xkvEcx3AY5KuOvXscgj2IroIYxHp0y4xtDAiqjIqOJFRQzMNxA5PGOa56laUtD2cNgqdNcy3Na6TFjuUcI6tgexFW5Y8QwP7kH8f8A9VQMu/TZuvC5/KtKaPdpwYdgrVNNXubyfuNDo1D20y/3kP8AKoGQS2oU/wASD+VT2LcgeoxUMH+q25ztJX8jW0DOlvYpQEghj95eD9a6XwhhLq5PacAj6r1/Q1zE7CK4cHo/zD+tdFps8dlY2bk/Pv3n6Hg/pRB8sjCr7rsX9UhzcvdqMiPCP9Dn+R/nUPnmeLyoOW3Ah+yn1re0+NZbeR2AZJmJ9QR0/wAax7yzOnzfJk27fdPofQ0VFrc5qvxM2LK585dknyzoPmHr7j2qxisWORZChyUkT7rj+RrQgvAzBJwI5D0/ut9D/SnGV9yEyw4rIutLt5HZ0DRSHqUOB+XSth+lVnq7J7jME2N5CfkaOVf++TTWNwvDQSD/AHSD/Wts1C/Wk6aJM2KSUniKbPutXIxck4K7R/tMP6VZgTJqy8dYVo2sNJBbIcZkYE+g6VdGGGKoIxU1Yjk6VgirFTUbIkF4hyKy1kZSVcYNdQpDDBqhf6eswLpw1OwJ9zND5FVb2BLm3lhf7silT+NPO+FysgxUh5GRUlHefD7U31PwxbGc5urUm1n/AN9OM/iMH8a6SvNvAV/9i8TT2D8Q6hH50f8A11QYYfiuD/wGvSa9SjLmgmeXWjyzaCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkZlRSzkKoGSScACsPX/FWmaLIIJ5HmvWGVtYF3yH3I6Ae5xXDapf6p4icrqLi10/PFlC33x/00b+L6DisqlaMPU1p0ZT9DQ8WeJX1ln03RJXWxU4ubyM48z1jjPp6sPwrH0+zjiRUiQIi8BQOlXUgVYwiKFQDAAGABT0ASvPqVHN3Z3wgoKyJ4owoqXcKrGT3qJ5qkstvIBVOafrzUM1xgcmqE9xxSCw66nJzzWTe3XkxlgC8jHaiDqzHoKZe3qxI7O2ABya0PDWlO8n9o36bXxiGNv4F9T7mmO5b0my/suwMkuGvJ/mkb/a/wHar9iV8xDkY2kfjkVXmY3dwqx9G4X2X1qJGNvM8MwBI9RwR60rkNm45VBl2Cj1JxWLfxw3Mm63BVs/NIOA3+NPYRsdxRTjoTziqzTPNL5Vupd/bt/hRcV7gypEuS1QtM8zbIEeRv9kVftdHLNvvW3f8ATNTx+JrUWJIkCxoFUdgMUWHYw7fS5HYNePx18tf6mtSNEjQIihVHQCpG600UDsJimkgU5jxUTUxlHU7SS6kieKUIUyORnr3FUbzSI2iCqC793bkn/CthjSrmhOwrHNJpwtr2FSBkKD+taWlDarqR91iKJ/m1Vv8AZCj+v9abOTa6kiDhZwWH6ZpxeppTe6OV1ZPKn1KPHRmIHsRmqcUe+1DEdMGtnxZCYrxpSPkmixn3HX9MVlWcqm1Ze+0/yqmtT1MO702bFnEJbORR1KGtS1h8zTEH96ID9KzNEJZMDpitrS/+PFF7rlfyOK2oK5zuWtjIsTwPY1Cf3dzcx/7W4fQj/wCtU92UtLmQMwAY7hVGW7Sa7LrnGzGccHB/+vTWjsTTdpEdzby31xFb2wLSk8Y/X9K6a0hhRBxufGwAjp2xil8GWR/e38o+98kefTuf6VfubJpb2S7tlykZy6ju3qK0lHS5lWd25djQ0sfZFWzY5QDMTeo9PrV2WNZEZJFDKeCCODWTDOk0ex+QecjqD6irsV0Ywq3TcHhZccH6+hqYy6M4k+5k3unzWrmS3Bkg67f4l/xFMiuQy7WAdO4PNdGRWfe6dDcMXwY5f769/r60nDsOxUSZwMwScdNj8j8+tSC6/wCeqMh9eo/MVSks7qA/JtlX1U4P5Gq5upImxIkif7ykChOUQNfzFYZVgR6g5pnU1m+erkNwT6qcGrEEpJ4dv+BDNWqiFc1bZKvPGCKzYLkggfKT9DUs95IwxuCA9wOaxrSTsO5HeER5VfvfypYVZEUN1xUttak4eQEDqAepqaSP0rnsUmNRqmV8jmoQuKeKBsbc2kc6nIGfWsS7gezO45KVvhsUrKkqlWAIPrT3FscheXLWwt9St+ZbKVbgY7gH5h+K5r2qGRJoUliYNG6hlYdweQa8l1TR5I1keyAZGUhoj0Ndr8ONRW98L2tux23VkotpYj95NvC5HuoBzXVhXZuJzYpXSkdRRRRXYcYUUUUAFFFFABRRRQAUUUUAFFFFABRRUdxPFbQSTXEixQxqWd3OAo9SaAFnmjt4ZJp3WOKNSzuxwFA6kmvN9b8X3es+ZDozyWWn5x9qAxLN/uA/dX36/Ss/xDrdx4muCAWi0VD+6h6G5weHf/Z7hfxNRwRZxxxXFWxF/didtHD296ZHp9lFbhvKXDMdzuTlmPqSeTWrCmKZEgAqTftrlOom4xVSeTYcU5pveqs7hxg0gI3u155qCS9UCqdzEwJ2HiqUikfeNMC3Le7s45rPvLvYhd2wo/zioriVYkGMsznCooyzH0Arc0HQGLpeakA0w+ZIuqxf4n3p2C5BoGiS3Usd7qSbUU7ooD2P95vf27Vu6xP5aJbR8GQZb2Uf41pgADA6Vh66pjvI5WB8to9m7sCCT/WkxMs6IoEMs7sASSvP8IFQ3863MgYACGP+Mjlj7e1UhPHwFiV37YGTV620+W6YPe5SL+GMcE/X0pEle3im1ByI/wB3AvDP/QVuWdrFaxbIlx6nuT71LHGsaBEUKo6AdqkUU0hgFpjCpsYqJzzTYEDLUMnFTSNxVORsmkUBNIeaaM1IozSAjK0+NfWnFafjFAGJEd+pXB9JMflx/So/ERP2izZPvxAv+HenWJzeTN6uT+tGp/Pe7v8AnmqfqTQiYytK4a3aLqfh6Yof3irvjPvjpXnsDshKsCrqdrKeoPcV6NGy28E8DH92yFkz/Kszxd4Xa4kbUdJUecRulhH/AC09x7/z/ntbmV0enhaig2nszE8OX8cfEjhSvXNdBp92vlzAAj94SM9cHmuU0gCF2SZCkobkMOR3rUuJxHdZ3fLIgP4j/wDXWlK8SNHMn1aUO0b4BCtzn0NR/Z/tzrDAD+7O9sf3e9V082+lFvboXeTjArotLtv7GDRTMGmX77/3h2x7VpJO9yazt8J0G6OCzhitF4KhYwO/pWraQC3t1j6nqx9T3rD0dgt5ulGIpB/o5P8AD6j8e1dCDWqlzanHVnf3UZN/pe5mms8JIeSh4Vv8DVGC6K7op02sOGRhXSGqt1aw3AHnICw6N0I/Gs5QvqjEz4JBGuIH2r2Run4elSfa16TAxH1PQ/jVO4sbm3YmE+dH6dGH+NQJd4Owkqe6sKi7juNaGm5yMg5FV5DVYSIB8uY8/wB3p+VNeZgMgq49uDVqaKuNkt4XPMa59QMVJBZRk8F1HsxqNJlP3gy/UVetnTGd6/nTVmBYt7CI8l5D/wACq7DbQxHKIN3qeT+tQrcQxqA0ifnTGvwQRCCT6kcVyTknITRfprLUdoGEe6TO5jnmpqW4EDLTDVhhUL9aTRSY2lBwabmlzUjJVYMMGsu9aTR71dcssh4B/pEY6TQ9WB9wMkH1FXs4qK4ZJYnjkGUcFSPUGqUmndEuN9D0SGRJokliYNG6hlYdweQafXMfDi7a58J2sUjbprMtaSexQ4H/AI7tP4109epF3VzzJLlbQUUUUxBRRRQAUUUUAFFFFABRRTZHWNGeRgqKMszHAA9TQA24nitoJJriRY4Y1LO7nAUDqSa8p8S60/ii5XZvTRYiDHEwwbhh/Gw/u+g/E1J4l1xvE83lRArocL5UdDdMP4j/ALAPQd+pqmibj7Vw161/did1Cjb3pCwxljV6NMCiGLAqRjgVynSBIAqCQ5pzHNRsaAGMcVC7cc0sj1TmmwD6UDGzS4zzxWPeXLSXCwW0Zlnb7qD+Z9B706eaa8uhaWS75z1PZB6t/hXVaFocGmoWJMtw/Lyt1P8AgPanYVyv4e0QWn+kXZWW8cctjhB/dX2/nXQAelGBS0CAUjAMpDAEHqDS0UAMjijjGI0VP90YqQUClAzTAAM1KgpFWlY4pksSRsCqsj0+Z+KqO2aTZSQSNkVBjJp5BJqWOOkMYkealEeKlRMCnMvFAFYimSHajH0GalcVXuzttpm9EP8AKgRi6cMLnueaJj5h1L1VEwfoCaI5Ut7dSxy56KOpNR2AkZ75bgbXdhkegK1JK3BbQ31rIs0zEhcrjjmtXTLt0s7eO54cxrh+zcVm6LN8wVuuMH61q2ISSExOAyoSmD7Hit8P8RpTqcuj2M7XLC3lu0mkjVt643Dg5Hv9KrHRbGdIXcOFR8NhuxrW1bTg1mWgkdWjO8LnOfX9Kp6fFvzG8zFHGOldEmlK43JJ3TNS1t7HS4yttGqE9ccs349aZe6bLfIJ3TaycpGerD0NXtLhiWEMFzMvyuzcnI/zmsnU76cXcuJmjWM4ABqqk1y6jlUvpEW0uFZTHMCYye/VT/Stm3u2jQLcnKfwyjoR7+lc8khuW3FlWZupYYDfX0PvVmG8e3kMUqlWHBVqyjK2qOdqx02QQCDketRsay7ecf8ALu+z1Q8qf8Ksrdr0mHlt7ng/jWymmJEztVO6hinXbMgYe/arDmoHNMozJbApkwTMo/uuNwqq0M6nlUb3Vv8AGtSRqgPJqHBBYpIk2f8AVuPpg1ZVXyNyScf7Jq9bJ3q8gwKyqJRiNIzY4JH6RkfXir9ra7CGkIZh0A6CpakSudIdiVacBmhRUyrxVpENkYTNRvFg1cAFDAEVXKLmM5o8VEwq+6YqlOMHioaKUrkTnC1nzOQxq6xyDVCcfMag0LPg7Uf7J8TvBK22z1TABPRbgDj/AL6HH1Ar06vGNQt2ubV40YpKMPG46q4OVP5ivUvC2q/214fsr8gK8qfvFH8Lg4YfmDXbhp3XKzixMLPmRq0UUV1HKFFFFABRRRQAUUUUAFea+L9efXLuTTLByulQsUuplP8Ax8MOsan+6O579OlXfGuvS3k0ui6RKUVflvbpD9wf881P949z2Hv0wYYEhiSKFQsaAKqjsK5K9b7MTroUftSGKgwFUAKBgADgCrMMeO1OjjqYAKK4jsAcCoZDTnaoHegAZsVXllAHWmSy4qjNLnJJwBySaBkk0xY4Ws0i41C5NrY444kn6rH7D1b2pYI5tXbbbs0VmDh5xwX9l/xrqtNtYrS3SKCMJGowAKYg0nTLfToNkK/MeWc8sx9Sa0M0wU8CgBwpaQUtAgpQKAM0uKYAKkUU1RUmcU0JinAFV5G60+RqqSPzihsEhJGzUWMmlqRVqChETmp1XFCringUxCgUjUtNNMCJlqjq/wAunzH1AH5mtE1m62T5EUY/jcZ+g5pMGZ0MEcQVlQBz1PU01FI1G891Q/oakD/v/L9MVIU/4mbY6NCD+R/+vUolbmPGxt9RkXoN+4fQ/wCTWvp8uL2dD0OHH4//AKqzNZiMVzFKAcMNh9j1H9aVJ9k1tOOn+qf8en61tRdmD0Z1QYEViXEf2O82rwjfMn9RWnDJkdaW6gS6h2Nww5VvQ11SV0NoW2uQMSryvSQf1qprtmJF+0Rcow+Yr/OqMcstpcbJBtkHUdmHqK0ra5xkwYwfvRE4/Ks91yslaGIN5cvK+4gbRgYrqIreO80+D7UgZ9g+buPxqKKOxmlz5SrL12MMH8u9XywAwOlVTp8o27mDdafcWpLQEzR+g+8P8aihvCQUbr3VhzW8z1WuYIbgfvo1bHQ9x+NU6fYmxQW5IwI3K47HkVIbv+8h+q8ioZtOK58iYgf3X+Yfn1qmYriMndHn3Rs1PvRAv+ar9GFPRcmsvziOHDD2ZTUsU0eMkJR7QdzehUACpTIgHLKB9axFeMqCcY9zUsaNIcRg49cYFc9WpzMq5ovcr0j+ZjwPSrUROBnr3qrbW4jwT8zfyq0tZoCzGasp0qrHVmOtYmch1ITTjTTVMkilb5aoTHk1flHFZ8/U1Ei4ldzVKZuatyVnXTcnFZs1QEjrXUfC99llq1rk4ivS6j0V0VsfnurkYiT1rrPhmp8zXH7G4jT8RGp/rW+G+MwxPwHb0UUV6B54UUUUAFFFFABXH+MvEE0ch0jR5At665nnAyLZD/7Oew/Gui1S4kjgZLY4mYY3f3PeuMexS3DhQSzsWdzyzsepJ9a569RxVkdFCmpO7Ma0torO3WCAEKOpJyWPck9yasxpmpWhIalOFFcB3gcKKhds0O2ajY4FIBjtVO4mwOKS5uBkgVnXNwkcbSTOFQdSaBjp5wqM8jBUUZJNQ2NjLq5WW4DRWGcrH0aYep9F9u9Lp1g+pSC4vkZbYHMUDfxf7TD+ldXBGABgcUxEdvbqiqqqFUDAAHSriLgUqpingUAIBS4paKBBSgUAZpwFMAAp4FIBTs4piYEYqNmpWaoJGxQ2CQkr1Aaf1NOC5qShqLUyrQoxUiigQKtO6UtMY0xCE0lFFIYlZGqtuvoU/uru/M//AFq2DWBI3m6nO3ZW2j8KTEyrISmosCewrRGPtEEn95Wj/r/Sor6DdbzTD70cu78MAH/PtSRP5lt8v34yHH4UC2F1K1+027xjhjyp9D2rBgO5Gil4DfKw9DXWHDqGXlSMg1iatZbC1xEOD98D+dNOzuU0P025baYpT+8Tgn19DWrHLXNxyZZSCBKo4J6MPStO3uA4wcq3dT1FdkJ3QkzSnjiuY9kq5HY9x9Kyrm0ntxuiJlQdx94fh3q6H4pwkNU4pg0Z0Opbl2TKJAD1PUVfjv8AI+SUNn+F+34024tYLk7pEw/99Tg1Rl06RMmFxIPQ8GotKOwrGst52kjZfdfmH6c1IJlcfKwNYSvJAPnWRPqOPzpxu1YcsjU1Ua3Ea8j1Xdsms03PGF3fgaRZpX43j8RT9oguXzIq9eT6UoiEnzTBcdQuKqxz+VyUUn13Uj3rHon5ms6lRJaFI0lManKog+gq3A+6ublvmGPmAPoK19GxLEJs7i3f2rlHc116VInWmL0qSMVSBliOp0qKMVOorRGTHGjFKKXNWSQTcCs2Y1fum4NZsrVnI0iVZzis6Y81cuG5NZ8zc1maIdH1rsfhajf2FeXJ+7c30siH/ZGE/wDZK4O8ufstlPP3RCR7nsPzxXrHhXTv7J8OadZEYeGFQ/8Avnlv1JrpwsfebObFS91I1aKKK7jhCiiigAooooArTwgg4FYt9bcEgV0ZGRVK5hyDxWVSF0a052Zx1xGVJqjKcV0d/bdcVhXMJBNcE4WZ3wldFBiBkmqd1OAMCn6hIYxgViXd3sdY1Rprl/uRJ1Pv7D3rM0FurhIEMkp4zgAckn0A7mpNN0yW4nW71FQoXmGA87P9pvVv5Va07Rykq3d+wlusfKo+5F7D3961wKYriwpV6NcCoYE4qytAC4owakApwWnYm5FtNG01NtoxTsFyILTgKftppOKLCuB4qNmpW5qM8UmMRmwKhOWNOPJpyrSKEVakApQKeopiGhafjApTTSaBCMabRRQMKKKKQCMdoJPQDNc5YkuzSN1dya3b99llO3+wf5Vh2o2QLntSYmacAWaK5jPQsVP5Csm0dreYq/3lO1q1bM7bqZM/LIBIv8j/AEqprVuY2+1IOOkgH6GgOhZtWCO0B6ffT3B7fgaldM5rNil8yNQWw6nKsOxq/bT+dlJAFlXqPX3HtQNMxNV04oDJboSvUoo5H0rMguAQA7bgOhB5FdjItYmoWEMkxYrtY87l4Na0tdEJorRT3AI8uVJl9G4arAvWU4kjKn36fnWfJYzR58p1ceh4NQfaZ4DiRJFHuMj862vJC1N5blyMogI9c07zpyPuqtYS38TH5kGfVTg1YS8XHEsg9jg1SqBc02eQ/efH0qtKkT/fVX+ozVZron+NT+GKTzyeq5/3TmnzICQW8P8ACm36Eip47aMf3h/wI1BFKpI3Bh/wGluLpQu1NxP0NTJxSuPQbOke7AZ8f71VpNvqx/Gml2Y5warXU3kxlmGT0VR1Y9hXK9XcLoXy3u7mO0hOHfliP4U7n+ldxYW6wQJGgwqjAA7VkeGtKa1iae5wbqbl/wDZHZR9K6SNeKB7DlWpkFIq1Ki00iWyWMVYUcVCvAp27ArRaGb1HMcVE74FI71XlkobGkRzyZJqhM2BU0smAaz7iXrWTZokQzvVNzk0+R8mmADqTgDnNIon0ax/tXxFptl1jR/tcw/6Zx4wD9WKj869hrhvhhpxNtc63MuHvTsgB/hhUnH/AH0cn8q7mvRoQ5Yep59efNP0CiiitjAKKKKACiiigAprrkU6igDOuYQwNYd9agBj0A711Eq8Vl3toJ1IkGU/u+v1rnqQudFOdjzG9W51C7aDTVwgOHunXKL7L/eP6Vp6ZpFvpyMYwXmf78znLv8AU/0rp7i2CDCqAB0AHSs+ZCM1xyjY7IyuZso5pqDmpZV5pI1+aoLLMQwKfSKMClFAh6mpFNMApwqkJj80optKDTJFNRnk0880wqaAGnimMM1MFzS7KVh3KwTmnBamK00ilYdxlLRiigYZppNKTTaACiiikAUUUUAUNbbGnuP7xUfrWXLiOCPPBbpWhrx/0aEeso/kaqyIJYrdWOFYmMn0J6H8wKTJY+CUGKOX+OE8/wC73/StZgHXsykfgRWBaO0UzRyjDKdritSwcxv9nY/L1iPqPT8KENGffWTWpMkAJh/ujkr/APWqBJ9yg78Efdcdq6Qisy70uORmeE+VIeTjofqKLBYZFfowCzkI/Td/Cf8AClu0DIGHNZs9tNbgmVCB6jlajhmdPljcqD2HI/KnCXK7hcsMMVA4pv2iQNh1RvdTijz0zyGH1FdqkmK5Vnt4XbLxqT64qu1lEfub0+jVoHa/3SDQI6dkwMo2sw+7MCP9palihuF5AVx7HFaIiyaJCIlwOWqJRildhYz5ZJY+DC272YVCZZj/AMsyPqwqeQ5YknJqC4mSGMtIcKP1rmk7sdiOaRkQvNIEQda1PDukvcTLfXqEAcwxN/D/ALR9/wCVGiaO9zMl5qCFQpzDCf4f9pvf+VdhBFgDipBKw6KPGKsKtORalC4FUkJsaoqUcCmHApC1UTuSlsd6jaSomeoy1JsaiPZ6rzPSyPgVUlk61LZaRHcSVnTPnPNSXEtU3bNSMM5anRWj6rqNppMGd10375l/5Zwj77e3HA9zUMkqW8LzTNtjQZJr0D4eaG9hYSajeptv7/DlT1ij/gT645PufatqNPnl5GVapyR8zqreGO3gjhgQRxRqERV6KAMACpKKK9I80KKKKACiiigAooooAKKKKAAjIqCROtT0jDIpNXGnYybqDOaybmDrXSSpkVn3EOc8Vz1IXOinOxy08OCajRMGtm5t+vFZzptNcco2OuMrjKVaSlXrUlDxS5pAKdiqEGagu7yG1j3zOFFTEVz3ifT57xovKGVXnHvQCNWy1ezu32RSqW9M1oivPHhuVnt0W2McysPmA7d67+3z5KbvvYGaExNEyilxSrTqokiIppFSkUwigCIjFNNSkVGwqWUiNqSnGm0igooopAFFFFAGXrp+SAerk/oaqWp82KSEnDHlT6GrWuj5bdvRiP0/+tWdDlCzg4wal7ksuXcJuIFvIhiQDEqjvjr+IqKCbzECM2CPmRh1Bq3bTiJ/Mz+4lPzf7Lev0qDUrFoWM1spMZ5ZB/D7imG5ftbvewimAWXsezfT/CrRFc/FcJLGFfkevpV61u3jISYmSPs/cfX1oTGmXyOKo3NhbyknZsb1Tir4ZHXKMGHsahlbAplGDdaa68xSBv8AeGP1qkY7iP78RI9VOa3pX5qP5T3Fb0+VqzJcTC81d2HGD6EYqVGXGQxH0atKZo1HIB9qzp1ifP7tAPYUSaj1DlI3uQvCu31zVZ5M5JkaklhhzwgqGQwwIZJAAo9sk+w96xbctwsNnmSONpGLFR+p9K09D0h5ZUvL5AHHMcPZPc/7X8qNG0xpZUu75fn6xQnpGPU/7X8q6y3ipDtYdbxYFXEXFIi4FSgVSQmxV4pxamk4pjGmTYVmphakJqN2xSuUkOJpjtioml5qCabjrUjsE01UZpqbNNk9apSyUDFlkyajXk1Hksan03T7jW9UTTLJzGSN9zMP+WMf/wAUegH49qcU5OyE2krs1fBuijX9U+1XAB0qxkHy9p5hzj/dXg+5+lerVV0yxttMsIbOyiWK3hXaiD/PXvmrVelTpqEbHm1KjnK4UUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAIy5qtJHmrVNZc0mrjTsZVxBkHisa7gIPSunlTOaz7mDcOlc9Snc6Kc7HNMuDQoq/c2+D0qmVwa5HGx1qV0LRSClpDCgqGFFAoENEK7s4BPripQKBTqYgBpwOabilHFMQ+mMKWkpiGGmEVKRTGFSUiJhTCKmNMYUiiOilIpKkYUUUUAZ2uL/AKGr9kcE/wAv61mhd9jcAEBhhgT7Vt6hD9ospoh1ZTj69qxNMYSja3R1waTJYsEnklkkGVztdfQ1pWk/khY5GzCeI5PT2NVp7QzWyXEHMyrtdf7+OD+PFUILojcuMoeCpo2DY1dQ0tZ28yAiOX9G+tZJlmtJNlwjKfXHB+laFpeNGoVD5sY/hJ+Zfp61aa5guEKgq47qw5H4UD3Mr7QjEMCVb1BxSvdSY4lz9RmluLC3JzGXjP8Asn/GqhsiD8s7/iKQWZIZ5D/Ev5UhmkxyU/I1GbOQD/X/APjv/wBeopYXVf8AXn8hQPUJZpCeqflVSWVh1dR9BQ8I6vJI3tnFQkRLk4HHJJ7fjTFqRzyqkbSOx2KOTWhommvJIt5eJhx/qoj/AAD1P+1/KotItDqEyXUy4tYzmFCPvn++f6fnXVQRdKY0iS2i5FaEa4FRwoAKnpoGPFOzxUW6jdTuTYexphNIWppakOwE1XmcU+V+DVGV6QxJZMVQuJyTin3EmAaz5HyTQMV5KaBu600Ak0TS+SqKkbSzyMEiiTlpGPQCgBwSae6hsrBPNvrg7Y17L6s3oo6mvWfC2g2/h/TFtoT5kzHfPOw+aVz1J/oOwqj4K8NLolu9zd4k1S5AMz9RGP8Anmv+yP1PNdNXoUaXIrvc8+tV53ZbBRRRW5gFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADWXNV5Y8irVNZc0mrjTsZM8Iasu5tsE4FdHJHVOaEHPFc86dzeFSxzbKVNNFadzbdwKz5EKmuWUbHVGVxtFNzilqSx608VGDg1IOaaJYtLSgU4LVEjKSnkUmKAGUhFSYpMUrDIiKaRUzVE5pDRERTDT2NRO4FSyx1FRiQGjeKQElc26/Y9QlToofev8Aun/JroN9ZetQNJGs0QzJH1A6svpSYNEltMIrpkz+7mG9D/tdx/X86bf2cVwS6ny5v747/X1rMguFlhEZbHRo39D2NXYrvefLlASYDlex9x60XEuxlziW3bEo2ns69D+NRtcscFgGPYjrWy7ZqnLZwv8AwbT6rxSsPlII7lz/ABN9G5qTz2/2aiaxK8pMQPdc1C9vJ/z3H/fP/wBegNSd7hv9kVTuLjqS4FNkg4+eVj9OKhKRpyQAfUnNOwtRhkaQ4UFvftRaWp1G78kf8esR/fMOjH+4P601mkuJltbTPnSDJcjiNe7f4V1OnWcdrbRwRDCIMe59z709hpFi3iAACgAAYAHatCJMCmQR4qwBQMUcUuaSigQUZooNAATUTtSs1QSvgUDGSvVOV8U6V6pzOaAIbh91V1GTTpDk0SSRwQvLKwVFGST2oASeWO2hMknQcAAZLHsAO5rvfAXhl7RRq2rxAalIP3UZ5+zIe3+8e5/CqfgPw1LJcR61q8WwgZs7ZxzGD/y0Yf3j2Hb69PQa7aFG3vSOKvWv7sQooorqOUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARhmq8qVZpGUNSauNOxmyxZFZl3bdSBW+6e1Vp4sg8VjOFzaE7HLSJtOKZWleQYJwKz2UiuOUbM7IyuhM09WqOjNTcZZVqduqsGpd9VcVictSbqi3UbqLisTbhTS9RFqQmi47DneoSc0pNRO4AqWykhXbFU5WzSyy5PWoC+akY4Mak31DuAFNL0DJWlxUbS5qF2pgbmkBRu7FldpbboTkx+/t/hVUuH+SUHcP4W4IraJqGWNJRiRFYe4osKxnRyyIMLO2PRxu/XrUjXcg6+W30yKkktLcDO0j6MapT28ZzhnH0NILMle7dh91P++v8A61VZLl+7Iv4Zppt0HJZz9TUbQx/3M/XmnZhqRvPubG9mPoB/hVea4EUgjVQbhx8kY5Zj/T8a0rOylvbee4iIttMtgWuL1l+UY/hjH8TnoB0zS6JpqLM96YTG8n+rRzuZF/2j3Y9/6dKrlsrslauxo6Dp32OAtIwe4kO6R/f0HsK3oY+lV7VOBWgi4FIscowKWiigQUUUUAFMZsUM2Khds0AI71UmenytVWRqBkbtzUDmnSPzULMMEsQAOST2oAjkKqrO5CqoySegrofBHhp9Xmg1fU0K2EbCS0tyP9cR0kb/AGe4Hfr061/B/hw+JLgXt8rDRomxHERj7Uw7n/YH6mvVlUIoVAFUDAAGAK66FH7Ujkr1re7EWiiiuw4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAjNROlS0UrBcy7mDOeKy7i2x2ro5I8iqc8Ge1Yzp3N4VLHMyxle1QNkVuXFv7VnzQYrklBo6ozuUc0oaklG2oC+KzNVqWQwpd1VPNppmx3ouFi5vFNaQVSM1MaUmi4WLMkwFVZZs96ikaoWalcY55KjMlMJpppDJPMoDGo1U5qdUxQA05NIKkIpp4oAaTUbyBRRK4UGqUr5NADpZc1XZvWkJ7moAZbm7jtLKF7m8k+5DH1PufQe5ppXE3YbcTpEheRgqDua6bwx4KutZ2XWsrJaaZ95YD8ss4/2v7q+3U+1dH4T8DRafNHf6y6Xd+vKRAfuoD6jPVvc/hUPxJ1+RNuhae5W4uE3XMqnmKI8YH+03I9hXVGkoLnmcsqrm+SBzmv6imuahFa2CLFoOnNsgRBhZpF43cfwjoPzqaGPpxVaxt0iijjjXaiAAD0FasEfNc0pObuzojFRVkS26YFWBTVGBTqQwooooAKaxxQxxUTtQA2RqhZ8CkkcVWkkoGEr1Ulellkqq7UAI788nitLwp4ffxPcLPcqy6HE3Jzg3TA/dH+x6nv0FReF/D8vie6ZpN0WjRNiSQcG4IPKL/s+p/AV6/BDHbwxwwIscUahVRRgKB0AFdVGjf3pHLXrW92IsaJFGscaqiKAqqowAB0AFOoortOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmOmelPooAozRZ7Vn3EHXitx1DCqs0PqKynA1jOxzNzb9eKyrmNlJwK6u4t+vFZd1a5zxXLOmdUKhzbMQaYWNaFxakE8VUeEg1g1Y3TuQbjRuNPZKYy1IyNmpnJp5Q05UoGQ7TS7anK4puOaAERakpOlNY0CEY1FI4ApJHxVWR8mgY2VyTUDU/qas6Lo914jvGtrFjFaxNi5u8cJ/sJ6t/KqjFydkTKSirsq6Zpt9rt99j0tQNv+uuWHyQj39W9F/pXrfhvw9YaBa+XZx5mcDzbh+XlPqT/ToKt6Npdpo+nx2enwiKBO3dj3JPcn1q4xCgliABySa9ClSUF5nn1arn6GZ4l1iHQtGuL6f5tgxHH3kc/dUfU/1ryCxE9xcS3d6/mXlw/mSv6t6D2A4H0rQ8W69/wkmsL9mbOlWhIh/6aydDJ9B0H4nvRaRjAxXLiKnM7LY6sPT5Fd7sv20fAq/GuBUdumFFWBWBuFFFNJoEOprHFNLVGzUDB3qvI9EriqssnpQASPVWWTGaSWTAqo7ljQA8tmrfhvQpvE94QGaLSIWxPMvBlP8AzzQ/zNN8NaHP4nuSqM8Wkxtie4XgyEdY0P8AM9q9fsrWCxtIra0iSGCJdqIowFFdNGjze9LY5q1bl92O4tpbQ2drFbWsaxQRKERFGAoHapaKK7jhCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACggEYNFFAEEkII9qo3NvweK1ajkjDDiolG5cZWOZuLfGeKzbiD0FdTcW+c8VmT23tXLOmdUKhzckRFVytb01t7VTktsHpXO42N1K5mbKTGKuvFioTHz0qSyuVzRsxVpUqKfgUgKzGoJGwKe7VVlfJoGRyNk5qE5Jp55NW9B0WbxFqTW0TNFp8BH2udeCT/zzU+p7nsKcYuTsiZSUVdjfD2jXPiS7eK3ZodOjO24ux1J7pH7+p7V65pthbaZZRWljCsNvENqovb/E+9OsbSCxtIrWziWG3iUKiKOAKkmljhiaWZ1jjQZZmOAB6k16VOkqaPOq1XUY+vM/G3ihtVafSNIf/QwTHd3S/wAfrGnt2J/Co/Evia58QSNaaRJJBpIysk4yr3PqF7hPfqayY7VIIBHGoVVGAB2FYVq/2Ym9Gh9qRn28aq4VFCqBgAdhW3aL0rLgQ+bjFblog4rjOsvxjCinUi9KWmIKjfink1XnlAFAxHfFV5ZsVG82c81Ulk5oAkklzVd5KjZ81DI4AJYgAdSaAFkbNXfDHh+48TzFiWg0dG2yTDhpyOqJ7di35VN4U8Ny+JpRcXO+HRUOOMq10fQHsnqe/Qeo9ZtoIra3jgt41jhjUKiKMBQOgFdVGhf3pHLWr8vux3G2drBZWsVtaRJDBEu1EQYCipqKK7TiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEZQw5qrNb5q3RSauNNoxZ7b2qhNb9eK6SSMEcVTlgBzxWE6ZvCoczNAfSqrR4PSukmtfas+e1x2rmlTaOiNRMx3GBVKc9a1LiIrmsu6G0GsWrGydzPuHxwKqsc0+U5JNV55fJiL7S7ZCoi8l2PAUe5PFIolgtbnUb6HTdOwLucElz0hjH3nP06D1Jr13Q9KttF0yGxsl2xRjkn7zt3YnuSayPA/h06LZPcXmH1S6w07Dog7Rr7D9TWh4j1+z0G0Et2xaWQ7YYI+ZJW9FH9egr0KNNU43e559ao6krR2Leq6ja6VYy3l/MsNvGMlj39gO5PpXmWuapdeJ5wLmNrfSEbdHat96U9mk/ov51Dey3ut3yX2sMNycwWqnMcH/AMU3+1+VW4YSTzWFau5aR2N6VBR1luNihGMKABTpYcKauxxgCiVcrxXOdBgxJidq1Lbiomh2vnHJq1CmFzSAmB4pS2BTV6Ux2waYCSPgVn3MmamuJO1U25NAETsRUDHJ5qWWqs0ixozuwVFGST2oAJZEjRndgqKMknsK3PCXhSXXZI77Vomi0kYeKBuGuD2LDsnt3+lTeCvCrauYdW1hCtiCJLa1I/1vo7+3cL+fv6fXXRofakclav8AZiNRFjRURQqKMBQMACnUUV2HGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU10DfWnUUAVXjx1FVpYQR0rTIz1qJ4vSocS1KxgXVpkHisLUbIlDgV2ckWc1SuLYMDxXPOlc6IVbHm08LK2CMVv+BNA+23i6xfx/6PCcWcbfxN3lP8h+dap0AX9yEf5Yc5kI9PT8a0PEGpPY2ostLVVuNoUNj5YV6Zx3PoKmlSUPfkVUquXuRI/FXiiLSALWyRbvVZB8kAPCD+/Iey/qe1cRFbzz3TXupTG61BxgysMBB/dQdlqezsEtt5Xc8kjb5JXOXkb1J71eSPFZVarqPyNaVJU15kEcPtVlEAFOAxS1kaBQaKKAI2jBpQu0U+mnpQAwnFVZ3xn1qWV8A1QmfmgYyRs/WomOBQzionfg0AMlcAEkgAVo+CvDv/CSXX2+/UnR4GxFEw4uXHc+qD9TVHw7or+K9TaH5l0m3b/SZRx5h/55qf5mvZIIY7eGOGBFjijUKiKMBQOgFdVCjf3mctety+7HccAAAAAAOABS0UV2nEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjKG61BJEccDNWKKTVxp2KjkwRlIuXPJPpWNdWm4knknkk966F0ByR1qtLEDnis5xuaQlY5Oe22dqrkYrpLq2BB4rIuLYqelcc6bR2QqJlGinOhU02sTUKKKKACoZXApZHwKo3EuaBjbiXrVFmyadK+ahzQAMabp2nXfiLUTp+nkpCmPtV12iU/wj1Y0/TbC81+/NlpnyRqf9IuyMrCPQer+1es6Lpdro2nx2djHsiTkk8s7d2Y9yfWuijR59Xsc9atyaLcdo+m2ukadDZWMYjgiGAO59SfUmrlFFd6VjgbvqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMoNLRQBVljqpLbhu1apAIwaieP0qJRuXGVjnbqy6kCsyWEqeldbJGD1rPubQNnArmqUex0wq9znCMVHI2BWjc2pXoKy7lSAa5nFo6VJMpzy5qjNJzT7lipIqlPKkETSzuEjXksakoex7npU+g6Pd+J5ttq72+mK2JbwDl8dVj9T/ALXQe9aPh3wpc68EutVV7XSiQyQdJLhf9r+6p9Op9q9Mghit4UhgjSOJAFVEGAoHYCuqlQvrI5ate2kSDStNtNJsIrPT4Vht4xwo7+5Pc+9W6KK7dji3CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBroCOOtVnj9RVuggHrSauNOxkXMAIPFY91Zg54rp5YiRxzVUWbStz8q9z3rCdO5tCpY4S806eSYR2kLTTHog4/EnsK3PDvguG2kS81opeXqndGmP3UP+6O5/wBo/hiust7eO3TbEoGep7mpacKEY6sJ15S0QUUUVuYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26705=[""].join("\n");
var outline_f26_5_26705=null;
var title_f26_5_26706="Benzalkonium chloride and benzocaine (topical): Drug information";
var content_f26_5_26706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzalkonium chloride and benzocaine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/7/25715?source=see_link\">",
"    see \"Benzalkonium chloride and benzocaine (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15826921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viroxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15826924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15826955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold sore:",
"     </b>",
"     Topical: Apply single dose to cold sore with applicator",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15826954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Cold sore:",
"     </b>",
"     Topical: Children &gt;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15826956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling(has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15826957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling(has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15826960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viroxyn&reg;: Benzalkonium chloride 0.13% and benzocaine 7.5% (0.6 mL) [contains isopropyl alcohol 70% v/v]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15826923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15827025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Product only available to dental professionals.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15826958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Prior to administration, clean lotions, ointments, or cosmetics from the lip using only warm water and a washcloth. Saturate the applicator with solution and apply to the cold sore. Allow a few moments for the lip to numb, then massage the solution (using the applicator) into the cold sore by rubbing firmly without damaging the skin. Avoid brushing with toothpaste or drinking fruit juices or soft drinks for at least one hour after application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15826926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of cold sores",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15826931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Local: Irritation, stinging (short-term)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15826927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzalkonium chloride, benzocaine, other ester-type local anesthetics, or any component of the formulation; ophthalmic use; use over a large area of body or &gt;3 times daily; longer than 1 week unless directed by healthcare provider",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15826928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical use only. If symptoms persist for 7-10 days after treatment then reassess.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15896779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15896777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15826934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Fruit juices and soft drinks may deactivate the active ingredient. Avoid drinking fruit juices and soft drinks for at least 1 hour after application.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15826937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzalkonium chloride is an antiseptic and disinfectant; benzocaine is an ester local anesthetic that blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87454 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26706=[""].join("\n");
var outline_f26_5_26706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826921\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826924\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826954\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826956\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826957\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826960\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826923\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827025\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826958\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826926\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826931\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826927\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826928\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896779\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896777\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826934\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826937\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/7/25715?source=related_link\">",
"      Benzalkonium chloride and benzocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26707="Advanced case 2 with answer";
var content_f26_5_26707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Bidirectional ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythm strip showing bidirectional ventricular tachycardia which may be a manifestation of digitalis toxicity. This rare, life-threatening tachyarrhythmia is characterized by beat-to-beat changes in the polarity of consecutive premature ventricular complexes. It may also occur in other settings, including catecholaminergic polymorphic ventricular tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26707=[""].join("\n");
var outline_f26_5_26707=null;
var title_f26_5_26708="Nepafenac: Patient drug information";
var content_f26_5_26708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nepafenac: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/3/39987?source=see_link\">",
"     see \"Nepafenac: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1615798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilevro&trade;;",
"     </li>",
"     <li>",
"      Nevanac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6859683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nevanac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691911",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling after cataract surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nepafenac or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses at any time while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11831 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26708=[""].join("\n");
var outline_f26_5_26708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615798\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6859683\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016896\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016895\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016900\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016901\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016903\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016898\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016899\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016904\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016905\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/3/39987?source=related_link\">",
"      Nepafenac: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26709="Cyclobenzaprine: Pediatric drug information";
var content_f26_5_26709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclobenzaprine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"    see \"Cyclobenzaprine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/23/33140?source=see_link\">",
"    see \"Cyclobenzaprine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amrix&reg;;",
"     </li>",
"     <li>",
"      Fexmid&reg; [DSC];",
"     </li>",
"     <li>",
"      Flexeril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cyclobenzaprine&reg;;",
"     </li>",
"     <li>",
"      Auro-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Ava-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Dom-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      JAMP-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Mylan-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Novo-Cycloprine;",
"     </li>",
"     <li>",
"      Nu-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      PHL-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      PMS-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Q-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      ratio-Cyclobenzaprine;",
"     </li>",
"     <li>",
"      Riva-Cycloprine;",
"     </li>",
"     <li>",
"      ZYM-Cyclobenzaprine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Nonparalytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"      see \"Cyclobenzaprine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Do not use longer than 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasm, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;15 years: Immediate release tablet: 5 mg 3 times daily; may increase to 7.5-10 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablet: 5 mg 3 times daily; may increase to 7.5-10 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release capsule: 15 mg once daily; may increase to 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild: 5 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate to severe: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: Mild to severe impairment: Use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amrix&reg;: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fexmid&reg;: 7.5 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flexeril&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet: May be administered without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release capsule: Administer at the same time daily; do not crush or chew",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amrix&reg;, Flexeril&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle spasm associated with acute painful musculoskeletal conditions (immediate release tablets: FDA approved in ages &ge;15 years and adults; extended release capsules: FDA approved in adults); has also been used for treatment of muscle spasm associated with acute temporomandibular joint pain (TMJ)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cyclobenzaprine may be confused with cycloSERINE, cyproheptadine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexeril&reg; may be confused with Floxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for cyclobenzaprine [Chile], but also the brand name for diclofenac [Argentina] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Chile] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]; Fluoxine brand name for fluoxetine [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, drowsiness, fatigue, headache, irritability, mental acuity decreased, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, gastric regurgitation, nausea, unpleasant taste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, arrhythmia, ataxia, dysarthria, hepatitis (rare), hypertonia, hypotension, paresthesia, psychosis, rash, seizures, syncope, tachycardia, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclobenzaprine or any component; hyperthyroidism; acute recovery phase of MI; CHF; arrhythmias; heart block or conduction disturbances; do not use concomitantly or within 14 days of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with urinary retention, angle-closure glaucoma, increased intraocular pressure, and patients receiving anticholinergic medications. Use with caution in patients with mild hepatic impairment; consider dosage reduction; avoid use in patients with moderate to severe hepatic dysfunction; extended release capsules not recommended in patients with hepatic impairment of any severity (mild, moderate, or severe). May cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not effective in the treatment of spasticity due to cerebral or spinal cord disease or in children with cerebral palsy; shares the toxic potentials of the tricyclic antidepressants, including prolongation of conduction time, arrhythmias, and tachycardia; the usual precautions of tricyclic antidepressant therapy should be observed; hyperpyretic crisis seizures and death have occurred when used in combination with MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F155293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Cyclobenzaprine may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Cyclobenzaprine may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome.  Management: Seek alternatives.  If these agents are given in combination, monitor for seizure activity and signs and symptoms of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5635799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases bioavailability (peak plasma concentrations increased by 35% and AUC by 20%) of the extended release capsule; avoid ethanol",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4844795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of muscle spasms and pain; improvement in physical activities",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Centrally-acting skeletal muscle relaxant pharmacologically related to tricyclic antidepressants; reduces tonic somatic motor activity influencing both alpha and gamma motor neurons",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release tablet: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release tablet: 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4, 1A2, and 2D6; may undergo enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 33% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Normal hepatic function: Range: 8-37 hours; immediate release tablet: 18 hours; extended release capsule: 32 hours; impaired hepatic function: 46.2 hours (range: 22.4-188 hours) (Winchell, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release tablet: ~4 hours (Winchell, 2002); extended release capsule: 7-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily renal as inactive metabolites and in the feces (via bile) as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 0.7 L/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/23/33140?source=see_link\">",
"      see \"Cyclobenzaprine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; do not use prescriptive or OTC antidepressants, sedatives, or pain medications without consulting healthcare provider; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dizziness, lightheadedness, urinary retention, and dry mouth. Report excessive drowsiness or skin rash.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Winchell GA, King JD, Chavez-Eng CM, et al, \"Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2002, 42(1):61-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26709/abstract-text/11808825/pubmed\" id=\"11808825\" target=\"_blank\">",
"        11808825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13188 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26709=[""].join("\n");
var outline_f26_5_26709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057508\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057501\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155255\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155241\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057511\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057504\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057510\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155306\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155304\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057515\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057500\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057499\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155293\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155250\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5635799\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155252\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4844795\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057507\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057498\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057513\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057514\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057506\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=related_link\">",
"      Cyclobenzaprine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/23/33140?source=related_link\">",
"      Cyclobenzaprine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26710="Irbesartan: Pediatric drug information";
var content_f26_5_26710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Irbesartan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"    see \"Irbesartan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=see_link\">",
"    see \"Irbesartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;;",
"     </li>",
"     <li>",
"      CO Irbesartan;",
"     </li>",
"     <li>",
"      PMS-Irbesartan;",
"     </li>",
"     <li>",
"      ratio-Irbesartan;",
"     </li>",
"     <li>",
"      Sandoz-Irbesartan;",
"     </li>",
"     <li>",
"      Teva-Irbesartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1020153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin II Receptor Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1020188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"      see \"Irbesartan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use a lower starting dose of 50% of the recommended initial dose in volume- and salt-depleted patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Limited data available (NHBPEP, 2004; NHLBI, 2011; Sakarcan, 2001): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: Initial: 75 mg once daily; may be titrated to a maximum dose of 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;13 years: Initial: 150 mg once daily; may be titrated to a maximum dose of 300 mg   once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Proteinuria reduction in children with chronic kidney disease:",
"     </b>",
"     Limited data available: Oral: Children and Adolescents 4-18 years: Studies utilized a fixed dosage based on weight categories (see below); initial doses were approximately 2 mg/kg once daily; doses were increased after 3-5 weeks and after 8-12 weeks if needed, according to specific blood pressure criteria; median final dose in the largest study (n=44; median age: 10 years): 4 mg/kg once daily (Franscini, 2002; Gartenmann, 2003; von Vigier, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-20 kg: Initial: 37.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     21-40 kg: Initial: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;40 kg: Initial: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 150 mg once daily; may be titrated to a maximum dose of 300 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Use a starting dose of 75 mg once daily in volume- or salt-depleted patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nephropathy with type 2 diabetes and hypertension:",
"     </b>",
"     Oral: Target dose: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment necessary with mild-to-severe impairment unless the patient is also volume depleted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment is needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avapro&reg;: 75 mg, 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6894350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food. Capsules may be opened and mixed with small amount of applesauce prior to administration (Sakaran, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1020174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 25&deg;C (77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1020154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with other antihypertensives (FDA approved in adults); treatment of diabetic nephropathy in patients with type 2 diabetes mellitus (noninsulin dependent, NIDDM) and hypertension (FDA approved in adults); has also been used to reduce proteinuria  in children with chronic kidney disease either as monotherapy or in addition to ACE inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avapro&reg; may be confused with Anaprox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anemia (case report; Simonetti, 2007), angina, angioedema, arrhythmia, cardiopulmonary arrest, conjunctivitis, depression, dyspnea, ecchymosis, epistaxis, gout, heart failure, hepatitis, hypotension, jaundice, libido decreased, MI, orthostatic hypotension, paresthesia, renal failure, renal function impaired, sexual dysfunction, stroke, thrombocytopenia, transaminases increased, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1020159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to irbesartan, any component, or other angiotensin II receptor blockers",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6894225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function; use is associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure); deterioration may result in oliguria, acute renal failure, or progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation in patients with progressive and/or significant deterioration in renal function.  Hyperkalemia may occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution with these agents; monitor potassium closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1020160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Symptomatic hypotension may occur, especially in patients with an activated renin-angiotensin system (eg, volume- or salt-depleted patients receiving high doses of diuretic agents); use with caution in these patients; correct depletion before starting therapy or initiate therapy at a lower dose. Concomitant use of an ACE inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Irbesartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1020173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not significantly affect AUC. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6894351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, renal function, baseline and periodic serum electrolytes, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1020176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irbesartan produces direct antagonism of the effects of angiotensin II. Unlike the ACE inhibitors, irbesartan blocks the binding of angiotensin II to the AT1 receptor subtype. It produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors. Irbesartan does not affect the ACE (kininase II) or the response to bradykinin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F6894228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 3-6 hours postdose; with chronic dosing maximum effect: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &gt;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1020178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 53-93 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%, primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid gylcoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via glucuronide conjugation and oxidation; oxidation occurs primarily by cytochrome P450 isoenzyme CYP2C9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Adults: 11-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted via biliary and renal routes; feces (80%); urine (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1020197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=see_link\">",
"      see \"Irbesartan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication (prescription or OTC), herbal products, potassium supplements, or salt substitutes during therapy without consulting prescriber. Take exactly as directed and do not discontinue without consulting prescriber. Medication should be taken at the same time each day; may be taken without regard to meals. This drug does not eliminate need for diet or exercise regimen as recommended by prescriber. May cause dizziness or lightheadedness (use caution when driving or engaging in tasks that require alertness until response to drug is known); postural hypotension (use caution when rising from lying or sitting position or climbing stairs); or diarrhea. Report immediately swelling of face, lips, or mouth; difficulty swallowing; chest pain or palpitations, unrelenting headache; muscle weakness or pain; unusual cough; or other persistent adverse reactions. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Franscini LM, Von Vigier RO, Pfister R, et al, \"Effectiveness and Safety of the Angiotensin II Antagonist Irbesartan in Children With Chronic Kidney Diseases,\"",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2002, 15(12):1057-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/12460701/pubmed\" id=\"12460701\" target=\"_blank\">",
"        12460701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gartenmann AC, Fossali E, von Vigier RO, et al, \"Better Renoprotective Effect of Angiotensin II Antagonist Compared to Dihydropyridine Calcium Channel Blocker in Childhood,\"",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2003, 64(4):1450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/12969165/pubmed\" id=\"12969165\" target=\"_blank\">",
"        12969165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Portman RJ, Milliner D, et al, \"Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(6):1242-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/10835064/pubmed\" id=\"10835064\" target=\"_blank\">",
"        10835064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sakarcan A, Tenney F, Wilson JT, et al, \"The Pharmacokinetics of Irbesartan in Hypertensive Children and Adolescents,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41(7):742-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/11452706/pubmed\" id=\"11452706\" target=\"_blank\">",
"        11452706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonetti GD, Bianchetti MG, Konrad M, et al, \"Severe Anemia Caused by the Angiotensin Receptor Blocker Irbesartan After Renal Transplantation,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(5):756-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/17216246/pubmed\" id=\"17216246\" target=\"_blank\">",
"        17216246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Zberg PM, Teuffel O, et al, \"Preliminary Experience With the Angiotensin II Receptor Antagonist Irbesartan in Chronic Kidney Disease,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2000, 159(8):590-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/10968237/pubmed\" id=\"10968237\" target=\"_blank\">",
"        10968237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaffanello M, Franchini M, and Fanos V, \"New Therapeutic Strategies With Combined Renin-Angiotensin System Inhibitors for Pediatric Nephropathy,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(1):125-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/5/26710/abstract-text/18154482/pubmed\" id=\"18154482\" target=\"_blank\">",
"        18154482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13019 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26710=[""].join("\n");
var outline_f26_5_26710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708952\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184320\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184321\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020153\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020188\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184295\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184281\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6894350\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020174\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020154\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184364\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184362\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020159\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6894225\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020160\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184350\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184290\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020173\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184292\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184303\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6894351\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020176\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6894228\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020178\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020197\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=related_link\">",
"      Irbesartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=related_link\">",
"      Irbesartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26711="Histology case 3 with answer";
var content_f26_5_26711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Histology case 3 with answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correct answer is",
"    <strong>",
"     hereditary nephritis",
"    </strong>",
"    (Alport's syndrome) in panels A and B, which is characterized by hematuria, the development of renal failure, and usually X-linked inheritance. Panel A reveals thickening and fraying of the glomerular basement membrane; the minimal staining with anti-GBM antibody in panel B is a characteristic finding in this disorder. The presence of electron dense deposits in the mesangium (panel C) and marked staining with anti-IgA antibodies (panel D) are diagnostic of IgA nephropathy. Although IgA nephropathy also presents with hematuria, there is generally no family history of renal disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26711=[""].join("\n");
var outline_f26_5_26711=null;
var title_f26_5_26712="Erythema nodosum IBD";
var content_f26_5_26712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71344%7ERHEUM%2F53733%7EGAST%2F52528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71344%7ERHEUM%2F53733%7EGAST%2F52528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema nodosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with inflammatory bowel disease with red nodular areas on the shins which are characteristic of erythema nodosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early lesion in pyoderma gangrenosum presenting as a pustular and violaceous plaque with incipient breakdown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple active and healing lesions of pyoderma gangrenosum with cribriform scarring in patient with inflammatory bowel disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26712=[""].join("\n");
var outline_f26_5_26712=null;
var title_f26_5_26713="Treatment of HIV-2 infection";
var content_f26_5_26713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of HIV-2 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26713/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26713/contributors\">",
"     Geoffrey S Gottlieb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26713/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26713/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/5/26713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2193841\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in certain regions of the world where it is endemic, such as West Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/1\">",
"     1",
"    </a>",
"    ]. Although multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1, mortality rates among HIV-1 and HIV-2 infected patients with advanced disease appear similar when adjusting for CD4 cell count, age, and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/1-15\">",
"     1-15",
"    </a>",
"    ]. Thus, antiretroviral therapy (ART) plays an important role in patient management.",
"   </p>",
"   <p>",
"    This topic will address the approach to treatment of the HIV-2 infected patient. The epidemiology, natural history, clinical manifestations, and diagnosis of HIV-2 infection are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13030?source=see_link\">",
"     \"Clinical manifestations and diagnosis of HIV-2 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193849\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with HIV-1 infection, the following benchmarks are critical goals of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced morbidity and mortality",
"     </li>",
"     <li>",
"      Improvement in quality of life",
"     </li>",
"     <li>",
"      Durable suppression of HIV-2 viral load",
"     </li>",
"     <li>",
"      Restoration of immune function (as indicated by CD4 cell count)",
"     </li>",
"     <li>",
"      Prevention of HIV-2 transmission to uninfected sex partners",
"     </li>",
"     <li>",
"      Prevention of mother to child transmission",
"     </li>",
"     <li>",
"      Prevention of drug resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are scant data on HIV-2 infection related to these basic principles. For example, the selection of antiretroviral therapy (ART) for HIV-2 infected patients is complicated by the absence of clinical trial data. Routine viral load and drug resistance assays for HIV-2, which are considered key to the management of HIV-1 infection, are mainly relegated to research laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/18\">",
"     18",
"    </a>",
"    ]. It is also unknown as to whether treatment-induced viral suppression of HIV-2 is associated with decreased transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link&amp;anchor=H60762411#H60762411\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\", section on 'Risk of transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2194364\">",
"    <span class=\"h1\">",
"     INDICATORS OF IMMUNE FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD4 cell count is the main indicator of immune function in patients who are infected with HIV-1 or HIV-2 and is a strong predictor of disease progression and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. This single immunologic parameter is one of the key factors in deciding whether to initiate antiretroviral therapy or chemoprophylaxis to prevent opportunistic infections. In patients with HIV-1 infection, it has been well-established that untreated patients with a CD4 cell count less than 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are at risk for opportunistic infections and mortality. Studies have also shown that initiation of ART among HIV-1 infected patients with a CD4 count &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    is associated with decreased mortality from AIDS and non-AIDS related complications. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with HIV-2 infection tend to have a slower immunologic decline than those with HIV-1, once the CD4 cell count is &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    HIV-2 infected patients are also at risk for morbidity and mortality related to opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/1-15\">",
"     1-15",
"    </a>",
"    ]. Interestingly, levels of viremia in HIV-2 infected patients tend to be much lower than those seen with HIV-1 infection, even at stages of advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link&amp;anchor=H60762000#H60762000\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\", section on 'Lower levels of viremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193865\">",
"    <span class=\"h1\">",
"     CLASSES OF ANTIRETROVIRAL MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple classes of antiretroviral medications for the treatment of HIV-1 including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs)",
"     </li>",
"     <li>",
"      Nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"     </li>",
"     <li>",
"      Protease inhibitors (PIs)",
"     </li>",
"     <li>",
"      Integrase strand transfer inhibitors (INSTIs)",
"     </li>",
"     <li>",
"      CCR5 antagonists",
"     </li>",
"     <li>",
"      Fusion inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, HIV-2 has intrinsic resistance to some entire classes of antiretroviral medications, while within other classes, not all agents are considered equally potent. Generally speaking, NNRTIs and fusion inhibitors should not be used to treat an HIV-2 infected patient. Specifics about drug resistance mutations are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H989621\">",
"    <span class=\"h1\">",
"     HIV-2 DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance data are important in guiding the selection of antiretroviral therapy regimens. Generally speaking, HIV drug resistance occurs when viral replication continues in the face of ongoing drug pressure. However, there are some important differences between HIV-1 and HIV-2 in terms of drug resistance patterns. Much of the data below has emerged from specialized research laboratories; commercial HIV-2 drug resistance testing is not commercially available. Basic concepts and principles regarding HIV drug resistance are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2195002\">",
"    <span class=\"h2\">",
"     Nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most data indicate that HIV-1 and HIV-2 are equally susceptible to all nucleoside reverse transcriptase inhibitors (NRTIs) currently in clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. However, resistance data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ) may be favored as a first-line agent over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , when available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11422608\">",
"     'Assays for drug resistance testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Drug resistance is prevalent in treatment-experienced patients with virologic failure. Commonly seen mutations include those that confer high-level resistance to",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"      emtricitabine",
"     </a>",
"    </span>",
"    (eg, M184V) and most NRTIs (eg, Q151M) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In vitro data suggest that as few as two NRTI mutations in HIV-2 (eg, Q151M and M184V) can confer full resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/28,31\">",
"     28,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    maintain activity in the presence of mutations known to confer decreased susceptibility to other NRTIs (eg, K65R or Q151M alone or together); however, class-wide nucleoside resistance is demonstrated when all three major NRTI mutations are present (ie, K65R, Q151M and M184V) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/28,32\">",
"     28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance data also suggest some important differences between HIV-1 and HIV-2:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients failing thymidine analogues (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ) often do not have the expected thymidine analog mutations (TAMs) associated with the use of these drugs; this suggests that alternative resistance pathways may exist for HIV-2 compared with HIV-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29,33-36\">",
"       29,33-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some NRTI mutations are selected more frequently in HIV-2 infected patients compared with those with HIV-1 (eg, K65R or Q151M) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two key NRTI thymidine analog mutations (TAMS) (M41L and T215Y), which have a negative impact on HIV-1 drug susceptibility to NRTIs, appear to have no effect on HIV-2 susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed information on thymidine analog mutations is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link&amp;anchor=H15#H15\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Nucleoside reverse transcriptase inhibitors (NRTIs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2196338\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protease inhibitor (PI) class has variable activity against HIV-2. PIs with the greatest in vitro activity include: lopinavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/17,37,38\">",
"     17,37,38",
"    </a>",
"    ]. Drug susceptibility data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , amprenavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    have lower potency against HIV-2 isolates compared with HIV-1, and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/22,37-41\">",
"     22,37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HIV-2 protease contains natural polymorphisms that are commonly associated with HIV-1 drug resistance, including major mutations (eg,",
"    <span class=\"nowrap\">",
"     V32I/L,",
"    </span>",
"    <span class=\"nowrap\">",
"     M46I/V,",
"    </span>",
"    I47V) and minor mutations (eg, L10VI,",
"    <span class=\"nowrap\">",
"     E35G/R,",
"    </span>",
"    Q58E,",
"    <span class=\"nowrap\">",
"     A71V/I,",
"    </span>",
"    <span class=\"nowrap\">",
"     G73A/T)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29,32,39,40,42-47\">",
"     29,32,39,40,42-47",
"    </a>",
"    ]. These mutations are the likely reason for variable PI potency against HIV-2; in addition, these mutations may increase the risk of virologic failure in HIV-2 infected patients during PI-based ART [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/33,47,48\">",
"     33,47,48",
"    </a>",
"    ]. Detailed information on PI drug resistance mutation is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link&amp;anchor=H33#H33\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2196498\">",
"    <span class=\"h2\">",
"     Integrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited in vitro data suggest that integrase inhibitors have potent anti-HIV-2 activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Studies that have evaluated genotypic resistance among integrase inhibitor-naive patients with HIV-2 infection found no key mutations associated with resistance to integrase inhibitors at the pre-treatment baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    has a low genetic barrier to drug resistance that is well documented during treatment of HIV-1 seropositive patients. In one small study of HIV-2 infected patients, virologic failure during raltegravir-containing combination ART was associated with the emergence of key signature mutations that confer raltegravir resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/54\">",
"     54",
"    </a>",
"    ]. Additionally, the key HIV-1 integrase inhibitor resistance mutations, Q148R and N155H, confer resistance to HIV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. Thus, the development of integrase inhibitor resistance during ART may be a concern in HIV-2 infection as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/41,55\">",
"     41,55",
"    </a>",
"    ]. Of note, another key integrase inhibitor mutation, Y143C, does not confer significant resistance to HIV-2 by itself, but does in conjunction with ancillary mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link&amp;anchor=H13#H13\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Genetic barrier to resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link&amp;anchor=H49#H49\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Integrase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2196646\">",
"    <span class=\"h2\">",
"     CCR5 coreceptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5 coreceptor antagonists are effective against HIV-1 strains, which use the CCR5 coreceptor for cell entry. In vitro data and anecdotal reports suggest that CCR5 antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , may also be effective against HIV-2 as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. However, the clinical effectiveness of this drug class remains uncertain since HIV-2 may use other co-receptors for cellular entry (eg, CXCR4, CCR1, CCR2b, CCR3, CXCR6 and GPR15) with greater affinity than HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Furthermore, the susceptibility of CCR5-tropic isolates from HIV-2 infected patients with AIDS was lower than isolates from asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link&amp;anchor=H47#H47\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'CCR5 antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral tropism assays to determine treatment candidacy for CCR5 inhibitors are under evaluation in HIV-2 infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2195182\">",
"    <span class=\"h2\">",
"     Nonnucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 is intrinsically resistant to nonnucleoside reverse transcriptase inhibitors (NNRTIs), including second generation drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/66\">",
"     66",
"    </a>",
"    ]. Thus, this drug class should not be used in HIV-2 therapy and should be avoided in dual",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    infection as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356294\">",
"    <span class=\"h2\">",
"     Fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-2 is intrinsically resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    and should not be used for treatment of patients with HIV-2 or dual infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/22,69,70\">",
"     22,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357199\">",
"    <span class=\"h1\">",
"     WHEN TO START ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to examine benchmarks for HIV-1 infection and how they may apply to HIV-2 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183744\">",
"    <span class=\"h2\">",
"     HIV-1 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD4 threshold at which ART is initiated has continued to rise over the past several years; the 2010 Department of Health and Human Services (DHHS) guidelines and the International AIDS Society-USA Panel guidelines recommended starting ART in patients with a CD4 cell count &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/16,71\">",
"     16,71",
"    </a>",
"    ]. However, in 2012, the DHHS guidelines were revised to recommend HIV-1 therapy in all patients, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/72\">",
"     72",
"    </a>",
"    ]; the 2012 IAS guidelines are pending.",
"   </p>",
"   <p>",
"    Earlier initiation of ART for HIV-1 infection has also been influenced by reduced drug toxicity, coformulations that enable better medication adherence, and a greater understanding of the negative impact of HIV-1 replication has on other comorbidities, such as cardiovascular, kidney, and liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183751\">",
"    <span class=\"h2\">",
"     HIV-2 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the significant amount of science and clinical experience guiding treatment of HIV-1 infected patients in developed nations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/18\">",
"     18",
"    </a>",
"    ], there is a paucity of data on ART for HIV-2 infection or dual",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    infection. Specifically, there are no data regarding the optimal time to initiate therapy in HIV-2 infection. The following issues complicate clinical decision-making:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies suggest that ART-associated improvements in CD4 cell counts may be blunted in HIV-2 infected persons compared with those with HIV-1 infection, suggesting that earlier initiation of ART may be important [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, many HIV-2 infected patients with normal CD4 counts and undetectable HIV-2 viral loads may never progress to clinical AIDS or die of an AIDS-related cause [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using HIV-1 infection as the reference standard, various treatment guidelines generally agree on initiating ART in the following HIV-2 infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/68,77\">",
"     68,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All symptomatic patients, regardless of CD4 cell count",
"     </li>",
"     <li>",
"      All patients with comorbidities that may benefit from ART (eg, HIV-associated nephropathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CD4 cell count threshold for initiating therapy among asymptomatic HIV-2 infected patients varies among the WHO, French, and British guidelines, but lies in the range of 350 to 500 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/68,78,79\">",
"     68,78,79",
"    </a>",
"    ]. The Department of Health and Human Services (DHHS) guidelines do not make any specific statements on when to start treatment for HIV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is also recommended for pregnant women with HIV-2 infection to decrease the risk of perinatal transmission, although there are no clinical trial data demonstrating that such an approach is effective. In general, the risk of perinatal transmission is lower among HIV-2 compared with HIV-1 infected persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=see_link&amp;anchor=H1427133#H1427133\">",
"     \"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354169\">",
"    <span class=\"h1\">",
"     CLINICAL DATA ON ANTIRETROVIRAL THERAPY OF HIV-2",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11422537\">",
"    <span class=\"h2\">",
"     Importance of viral suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether immune recovery (as measured by increases in CD4 cell counts), in response to ART, is as robust in HIV-2 as in HIV-1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/30,33,74,75,80,81\">",
"     30,33,74,75,80,81",
"    </a>",
"    ]. However, among patients who attain viral suppression on ART, significant increases in CD4 counts are usually observed, irrespective of the ART regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/80\">",
"     80",
"    </a>",
"    ]. Viral suppression is also associated with a decreased risk of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354448\">",
"    <span class=\"h2\">",
"     HIV-2 monoinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials that have evaluated the optimal therapy for patients with HIV-2 monoinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/72\">",
"     72",
"    </a>",
"    ]. Only small cases series and other observational data are available. In addition, antiretroviral medications were often chosen based on restricted availability in locales within West Africa, where many of these studies were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Thus, there are more data, for example, on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    for dual NRTI backbone than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    , which are commonly used for HIV-1 treatment because of their favorable potency and toxicity profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11422492\">",
"    <span class=\"h3\">",
"     Observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in HIV-1 treatment, the majority of the studies have utilized three-drug combination therapy regimens; these regimens have mainly included a dual nucleoside reverse transcriptase inhibitor backbone of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in combination with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitor, lopinavir [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/84\">",
"     84",
"    </a>",
"    ]. Three clinical case series from Europe (76 patients), France (29 patients) and the Gambia (45 patients) support the effectiveness of",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    as part of combination ART [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/21,80,84\">",
"     21,80,84",
"    </a>",
"    ]. Within these cohort studies, ART has led to viral suppression in the majority of patients with significant improvements in CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/21,80,84\">",
"     21,80,84",
"    </a>",
"    ]. There is little clinical data on the use of other HIV-2 &ldquo;active&rdquo; PIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scant data are available on the use of other medications in HIV-2 infected patients. As demonstrated in HIV-1 infected patients, triple NRTI regimens are inferior to PI-based regimens in HIV-2 treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/84\">",
"     84",
"    </a>",
"    ]. Anecdotal reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    may be clinically effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/49,50,85,86\">",
"     49,50,85,86",
"    </a>",
"    ]. In addition, use of unboosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    has been associated with high rates of virologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and multiclass drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29\">",
"     29",
"    </a>",
"    ] while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted indinavir was associated with high rates of viral suppression in one small cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/33\">",
"     33",
"    </a>",
"    ]. In general, protease inhibitors should be given with low-dose ritonavir to boost serum levels of the parent drug (eg &ldquo;pharmacokinetic boosting&rdquo;). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No studies on ART for HIV-2 infection to date have looked at efficacy of second-line or salvage regimens in resource-limited or resource-rich settings. Consultation with an HIV-2 expert is warranted in determining treatment options in the patient with virologic failure on antiretroviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354176\">",
"    <span class=\"h2\">",
"     HIV-1 and HIV-2 dual infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only data on ART for",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    dual infection is based on a few case reports and case series; outcomes were poor, immunologic and virologic failure rates were high, and ARV resistance (usually related to HIV-2) was common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/48,87-90\">",
"     48,87-90",
"    </a>",
"    ]. Consultation with an HIV-2 expert is warranted for dually-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11422608\">",
"    <span class=\"h1\">",
"     ASSAYS FOR DRUG RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HIV-1 infection, drug resistance testing is recommended at initial diagnosis, to assess for transmitted drug resistance (TDR), and at virologic failure, to assess for acquired drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar approach to testing is desirable for HIV-2 infected patients. However, drug resistance testing assays are not commercially available for HIV-2 infection, which hampers the ability to select the optimal medication regimen for treatment initiation or modification. Fortunately, transmitted drug resistance has rarely been reported in HIV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. However, virologic failure in an HIV-2 infected patient on ART is associated with acquired drug resistance that affects multiple classes of drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29,36\">",
"     29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance testing may be obtained from research facilities that include laboratories in the United States (at the University of Washington; contact Dr. Geoffrey Gottlieb (email: gottlieb@uw.edu)) and Europe (contacts available at:",
"    <a class=\"external\" href=\"file://etudes.isped.u-bordeaux2.fr/achiev2e\">",
"     file://etudes.isped.u-bordeaux2.fr/achiev2e",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193896\">",
"    <span class=\"h1\">",
"     SELECTION OF AN INITIAL ANTIRETROVIRAL REGIMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2196659\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there are no clinical trials evaluating the selection of antiretroviral medications for the HIV-2 infected patient, so the optimal strategy has not yet been defined. Guidance on ART selection for the HIV-2 infected patient largely depends on in vitro drug susceptibility data from research laboratories and observational data from cohort studies.",
"   </p>",
"   <p>",
"    In HIV-1 infected patients, viral suppression secondary to combination ART is associated with optimal CD4 cell recovery and a reduced risk of drug resistance. As in HIV-1, simplicity (pill burden and dosing schedule) of the ART regimen is likely to improve adherence and reduce the risk of virologic failure. Until further data are available, a similar approach to HIV-1 treatment may be adopted for HIV-2 infection. Specifically, two NRTIs should form the backbone of therapy. In contrast to HIV-1, however, the third drug should not include any agent from the NNRTI class since HIV-2 is intrinsically resistant to these medications. An HIV-2 active PI (eg, lopinavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ) should be selected and given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacologic boosting. Based on available in vitro and clinical data, we suggest the following antiretroviral medications as first-line therapy of HIV-2 infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PLUS",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      -boosted lopinavir",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Where available, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    , coformulated as Truvada, which affords once-daily dosing and is well tolerated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     Zidovudine-lamivudine",
"    </a>",
"    must be dosed twice daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    is associated with significant risk of anemia. (See",
"    <a class=\"local\" href=\"#H2193912\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193904\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H353902\">",
"    <span class=\"h2\">",
"     HIV RNA assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV RNA monitoring is considered integral to HIV care and management. Viral suppression is associated with improvements in CD4 cell counts and a decreased risk of drug resistance. Similar observations have been made in HIV-2 infected patients. In contrast, any detectable viremia is associated with the emergence of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When available, viral load testing should be performed at baseline, and then periodically after starting ART (ie, six to eight weeks after treatment initiation and then two to four times per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/71\">",
"     71",
"    </a>",
"    ]. Availability of HIV-2 RNA testing is quite limited, but may be obtained from the following laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, contact Geoffrey Gottlieb at the University of Washington (gottlieb@uw.edu) or UW Lab Medicine Community Services (phone 800-713-5198 or commserv@u.washington.edu)",
"     </li>",
"     <li>",
"      In Europe, contacts are available at",
"      <a class=\"external\" href=\"file://etudes.isped.u-bordeaux2.fr/achiev2e\">",
"       file://etudes.isped.u-bordeaux2.fr/achiev2e",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H353953\">",
"    <span class=\"h2\">",
"     CD4 cell counts and clinical monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of these basic tools for monitoring treatment responses in the HIV-2 infected patient, clinical assessment and CD4 count monitoring take on additional importance. Declining CD4 cell counts on ART would be consistent with virologic failure and risk of disease progression. Any evidence of thrush would also be an early clinical indicator of a failing regimen. New opportunistic infections or clinical AIDS-associated events may also occur in the first months after initiation of ART related to advanced AIDS. Clinical and laboratory monitoring every three to six months is advised based on stage of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=see_link\">",
"     \"Primary care of HIV-infected adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary care of HIV-infected adults\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193912\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events related to antiretroviral medications are discussed in detail elsewhere. Of note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    are generally well tolerated. Monitoring of kidney function is important in patients taking tenofovir. Anemia, gastrointestinal upset, and headache are common in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    -boosted lopinavir is associated with diarrhea, lipid abnormalities, and lipodystrophy. Potential drug-drug interactions should also be assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2196701\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT OF OPPORTUNISTIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until further data are available specifically for HIV-2, clinicians should follow guidelines for the prevention and treatment of opportunistic infections for HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26713/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360298\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in certain regions of the world where it is endemic, such as West Africa. (See",
"      <a class=\"local\" href=\"#H2193841\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in HIV-1 infection, the main goals of therapy are to reduce mortality and morbidity and to attain viral suppression and improvement in CD4 cell counts. (See",
"      <a class=\"local\" href=\"#H2193849\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CD4 cell count is the main indicator of immune function in patients who are infected with HIV-2. Although patients with HIV-2 infection tend to have a slower immunologic decline than those with HIV-1, once the CD4 cell count is &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      HIV-2 infected patients are at risk for morbidity and mortality from opportunistic infections, as seen in patients with HIV-1 infection. (See",
"      <a class=\"local\" href=\"#H2194364\">",
"       'Indicators of immune function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-2 has intrinsic resistance to some entire classes of antiretroviral medications, such as the nonnucleoside reverse transcriptase inhibitors (NNRTIs) and the fusion inhibitors, while within other classes not all agents are considered equally potent. Within the nucleoside reverse transcriptase inhibitor (NRTI) class,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      appears to have the best drug resistance profile, while within the protease inhibitor class, lopinavir,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      have superior in vitro potency against HIV-2 compared with other medications. (See",
"      <a class=\"local\" href=\"#H2193865\">",
"       'Classes of antiretroviral medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no data regarding the optimal time to initiate therapy in HIV-2 infection. We recommend initiation of antiretroviral therapy (ART) among HIV-2 infected patients who are symptomatic or who have other comorbidities that may improve with HIV therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest initiation of ART in patients who have a CD4 cell count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H357199\">",
"       'When to start antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug resistance testing assays are not commercially available, which hampers the ability to check for resistance mutations prior to treatment initiation or during virologic failure on treatment. Clinicians may obtain drug resistance testing from certain research facilities in the United States and Europe. (See",
"      <a class=\"local\" href=\"#H11422608\">",
"       'Assays for drug resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To date, there are no clinical trials evaluating the selection of antiretroviral medications for the HIV-2 infected patient, so the optimal strategy has not yet been defined. Until further data are available, we suggest three-drug combination therapy with two nucleoside reverse transcriptase inhibitors plus a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted protease inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Based on limited in vitro and clinical data, the preferred regimen for the treatment-na&iuml;ve patient is:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus ritonavir-boosted lopinavir. (See",
"      <a class=\"local\" href=\"#H2193896\">",
"       'Selection of an initial antiretroviral regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because HIV-2 viral load and resistance testing are often not available, patient monitoring is usually dependent on clinical symptomatology and CD4 count monitoring. Clinical and laboratory monitoring every three to six months is desirable depending on the stage of disease. (See",
"      <a class=\"local\" href=\"#H2193904\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with an infectious disease specialist with expertise in HIV-2 infection is warranted in determining treatment options in the patient with virologic failure on antiretroviral therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/1\">",
"      Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/2\">",
"      Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/3\">",
"      Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/4\">",
"      Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/5\">",
"      Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/6\">",
"      Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/7\">",
"      Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/8\">",
"      Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/9\">",
"      Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/10\">",
"      Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/11\">",
"      Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/12\">",
"      MacNeil A, Sarr AD, Sankal&eacute; JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/13\">",
"      Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/14\">",
"      Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/15\">",
"      Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/16\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/19\">",
"      Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/20\">",
"      Egger M, May M, Ch&ecirc;ne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/21\">",
"      B&eacute;nard A, Damond F, Campa P, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS 2009; 23:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/22\">",
"      Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/23\">",
"      Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/24\">",
"      Cox SW, Ap&eacute;ria K, Albert J, Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 10:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/25\">",
"      Damond F, Collin G, Matheron S, et al. Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir Ther 2005; 10:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/26\">",
"      Boyer PL, Sarafianos SG, Clark PK, et al. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/27\">",
"      Smith RA, Gottlieb GS, Anderson DJ, et al. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 2008; 52:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/28\">",
"      Smith RA, Anderson DJ, Pyrak CL, et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/29\">",
"      Gottlieb GS, Badiane NM, Hawes SE, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009; 48:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/30\">",
"      Adj&eacute;-Tour&eacute; CA, Cheingsong R, Garc&igrave;a-Lerma JG, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, C&ocirc;te d'Ivoire. AIDS 2003; 17 Suppl 3:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/31\">",
"      Rod&eacute;s B, Holgu&iacute;n A, Soriano V, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/32\">",
"      Trevi&ntilde;o A, de Mendoza C, Caballero E, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 2011; 66:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/33\">",
"      van der Ende ME, Prins JM, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17 Suppl 3:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/34\">",
"      van der Ende ME, Guillon C, Boers PH, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/35\">",
"      Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/36\">",
"      Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/37\">",
"      Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/38\">",
"      Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008; 71:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/39\">",
"      Rod&eacute;s B, Sheldon J, Toro C, et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/40\">",
"      Masse S, Lu X, Dekhtyar T, et al. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother 2007; 51:3075.",
"     </a>",
"    </li>",
"    <li>",
"     Smith R, Ba S, Hawes S, et al. Toward Optimal ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug Resistance Testing Help Guide Therapy in HIV-2? In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/42\">",
"      Colson P, Henry M, Tourres C, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42:570.",
"     </a>",
"    </li>",
"    <li>",
"     Stanford HIV Drug Resistance Dtabase. Stanford University 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/44\">",
"      Pieniazek D, Rayfield M, Hu DJ, et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/45\">",
"      Damond F, Brun-Vezinet F, Matheron S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/46\">",
"      Rod&eacute;s B, Toro C, Sheldon JA, et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/47\">",
"      Ntemgwa M, Brenner BG, Oliveira M, et al. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007; 51:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/48\">",
"      Schutten M, van der Ende ME, Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N Engl J Med 2000; 342:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/49\">",
"      Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/50\">",
"      Xu L, Anderson J, Ferns B, et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 2008; 24:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/51\">",
"      Smith RA, Raugi DN, Kiviat NB, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 2011; 25:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/52\">",
"      Charpentier C, Larrouy L, Collin G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 2010; 24:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/53\">",
"      Gottlieb GS, Smith RA, Dia Badiane NM, et al. HIV-2 integrase variation in integrase inhibitor-na&iuml;ve adults in Senegal, West Africa. PLoS One 2011; 6:e22204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/54\">",
"      Ni XJ, Delelis O, Charpentier C, et al. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology 2011; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/55\">",
"      Roquebert B, Blum L, Collin G, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 2008; 22:2045.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2012b/Abstracts/44997.htm (Accessed on May 25, 2012).",
"    </li>",
"    <li>",
"     Armstrong-James D. Clinical outcome in a resistant HIV-2 infected man treated with raltegrevir and maraviroc: systemic response but failure to control viral replication in the brain. AIDS 2008 - XVII International AIDS Conference: Abstract no. TUPE0074",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/58\">",
"      Willey S, Peters PJ, Sullivan WM, et al. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res 2005; 68:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/59\">",
"      Espirito-Santo M, Santos-Costa Q, Calado M, et al. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors. AIDS Res Hum Retroviruses 2012; 28:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/60\">",
"      Peterson K, Rowland-Jones S. Novel agents for the treatment of HIV-2 infection. Antivir Ther 2012; 17:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/61\">",
"      M&ouml;rner A, Bj&ouml;rndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/62\">",
"      Sol N, Ferchal F, Braun J, et al. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J Virol 1997; 71:8237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/63\">",
"      Blaak H, Boers PH, Gruters RA, et al. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 2005; 79:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/64\">",
"      Borrego P, Calado R, Marcelino JM, et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther 2012; 17:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/65\">",
"      Visseaux B, Hurtado-Nedelec M, Charpentier C, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis 2012; 205:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/66\">",
"      Tuaillon E, Gueudin M, Lem&eacute;e V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/67\">",
"      Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/68\">",
"      Gilleece Y, Chadwick DR, Breuer J, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010; 11:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/69\">",
"      Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/70\">",
"      Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (Accessed on May 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/73\">",
"      Wilkin TJ, Gulick RM. When to start antiretroviral therapy? Clin Infect Dis 2008; 47:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/74\">",
"      Matheron S, Damond F, Benard A, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/75\">",
"      Drylewicz J, Eholie S, Maiga M, et al. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010; 24:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/76\">",
"      van der Loeff MF, Larke N, Kaye S, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on July 25, 2011).",
"    </li>",
"    <li>",
"     Yeni P. Points forts et Recommandations Extraits des Recommandations du Groupe d&rsquo;Experts Rapport 2008 &laquo; Prise en charge m&eacute;dicale des personnes infect&eacute;es par le VIH &raquo; sous la direction du Pr Patrick Yeni. In: Paris: Minist&egrave;re de la Sant&eacute; 2008; p.1-32.",
"    </li>",
"    <li>",
"     WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/80\">",
"      Peterson I, Togun O, de Silva T, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 2011; 25:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/81\">",
"      Drylewicz J, Matheron S, Lazaro E, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/82\">",
"      Gottlieb GS, Eholi&eacute; SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069.",
"     </a>",
"    </li>",
"    <li>",
"     Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-2074. (Discussion)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/84\">",
"      Benard A, van Sighem A, Taieb A, et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis 2011; 52:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/85\">",
"      Damond F, Lariven S, Roquebert B, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/86\">",
"      Garrett N, Xu L, Smit E, et al. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/87\">",
"      Borget MY, Diallo K, Adje-Toure C, et al. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, C&ocirc;te d'Ivoire. J Clin Virol 2009; 45:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/88\">",
"      Landman R, Damond F, Gerbe J, et al. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/89\">",
"      Rod&eacute;s B, Toro C, Jim&eacute;nez V, Soriano V. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect Dis 2005; 41:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/90\">",
"      Maniar JK, Damond F, Kamath RR, et al. Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma. Int J STD AIDS 2006; 17:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/91\">",
"      Ruelle J, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/92\">",
"      Ruelle J, Sanou M, Liu HF, et al. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses 2007; 23:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/93\">",
"      Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/94\">",
"      Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26713/abstract/95\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16252 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-C2C579228A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26713=[""].join("\n");
var outline_f26_5_26713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H360298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193841\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193849\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2194364\">",
"      INDICATORS OF IMMUNE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193865\">",
"      CLASSES OF ANTIRETROVIRAL MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H989621\">",
"      HIV-2 DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2195002\">",
"      Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2196338\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2196498\">",
"      Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2196646\">",
"      CCR5 coreceptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2195182\">",
"      Nonnucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356294\">",
"      Fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H357199\">",
"      WHEN TO START ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H183744\">",
"      HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H183751\">",
"      HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354169\">",
"      CLINICAL DATA ON ANTIRETROVIRAL THERAPY OF HIV-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11422537\">",
"      Importance of viral suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354448\">",
"      HIV-2 monoinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11422492\">",
"      - Observational data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354176\">",
"      HIV-1 and HIV-2 dual infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11422608\">",
"      ASSAYS FOR DRUG RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193896\">",
"      SELECTION OF AN INITIAL ANTIRETROVIRAL REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2196659\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193904\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H353902\">",
"      HIV RNA assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H353953\">",
"      CD4 cell counts and clinical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2193912\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2196701\">",
"      PREVENTION AND TREATMENT OF OPPORTUNISTIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H360298\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13030?source=related_link\">",
"      Clinical manifestations and diagnosis of HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38343?source=related_link\">",
"      Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=related_link\">",
"      Primary care of HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26714="Inherited thrombophilias in pregnancy";
var content_f26_5_26714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited thrombophilias in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/5/26714/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/5/26714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7898243\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilias are genetic conditions that increase the risk of thromboembolic disease. During pregnancy, the thrombogenic potential of these inherited disorders is enhanced because of the hypercoagulable state produced by normal pregnancy-associated changes in several coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistance to activated protein C increases in the second and third trimesters",
"     </li>",
"     <li>",
"      Protein S activity decreases due to reductions in total protein S antigen",
"     </li>",
"     <li>",
"      Fibrinogen and factors II, VII, VIII, and X increase",
"     </li>",
"     <li>",
"      Levels and activity of the fibrinolytic inhibitors, thrombin activatable fibrinolytic inhibitor (TAFI), plasminogen activator inhibitor type 1 (PAI-1) and PAI-2 increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best documented potential sequelae of the hypercoagulable state are maternal deep venous thrombosis and pulmonary embolism; arterial thrombosis is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .) An association with adverse pregnancy outcome has been suggested, but is controversial. Even if such an association exists, the argument that thrombophilia causes thrombosis at the low flow maternal-placental interface resulting in placenta-mediated complications does not meet the criteria for establishing causality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/5\">",
"     5",
"    </a>",
"    ]. Hill's criteria for causation include: (1) strength of association, (2) consistency of association, (3) temporal relationship, (4) specificity, (5) biologic plausibility, (6) biologic gradient, (7) coherence, (8) analogy, and (9) experimentation.",
"   </p>",
"   <p>",
"    This topic will discuss issues related to inherited thrombophilias in pregnant women. General issues related to hemostasis and discussions of specific thrombophilias are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898251\">",
"    <span class=\"h2\">",
"     Types of inherited thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thrombosis. The most frequent causes of an inherited (primary) hypercoagulable state are the factor V Leiden mutation and the prothrombin gene mutation, which together comprise 50 to 60 percent of cases. Defects in protein S, protein C, and antithrombin (formerly known as antithrombin) account for most of the remaining cases. Each of these disorders is discussed separately, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden mutation (FVL) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prothrombin G20210A gene mutation (PGM) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein S deficiency &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein C deficiency &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antithrombin deficiency &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although collectively present in 8 to 15 percent of Caucasian populations, these disorders appear to be responsible, at least in part, for up to half of maternal venous thromboembolism (VTE) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homozygosity for MTHFR polymorphisms (C677T, 1298C) is a relatively common cause of mildly elevated plasma homocysteine levels, but these mutations do not appear to increase the risk of VTE in pregnant or nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mutations in genes for clotting factors exist, but are less common and their relationship with VTE is unclear. Although elevated factor VIII is a prothrombotic risk factor for a first unprovoked VTE, elevated levels have not been shown to be a risk factor for recurrence and should not be viewed as an inherited thrombophilia. Furthermore, assays for factor VIII levels have not been standardized and there is no information on the interpretation of factor VIII levels in pregnancy with respect to prothrombotic risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898258\">",
"    <span class=\"h1\">",
"     PURPORTED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilias increase the risk of maternal thrombosis and it has been hypothesized that they cause thrombosis at the low flow maternal-placental interface resulting in placenta-mediated complications, such as miscarriage, fetal loss, preeclampsia, fetal growth impairment, and abruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898272\">",
"    <span class=\"h2\">",
"     Maternal venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of VTE is augmented during pregnancy because of the aforementioned physiological changes in the coagulation system, as well as predisposing physical changes, such as stasis in large veins of the lower extremities from uterine compression, decreased mobility, and the delivery process (especially cesarean birth). However, the absolute risk remains low at about 0.1 percent.",
"   </p>",
"   <p>",
"    The risk of VTE is magnified in pregnant women who have certain inherited (and acquired) thrombophilias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/9-13\">",
"     9-13",
"    </a>",
"    ], and is even higher in those with multiple thrombophilic defects in addition to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/14\">",
"     14",
"    </a>",
"    ]. Data suggest that at least 50 percent of women with VTE during pregnancy have an acquired or inherited thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/15\">",
"     15",
"    </a>",
"    ]. All thrombophilias, however, do not have the same degree of risk for thrombotic sequelae during pregnancy. The occurrence of thrombotic events is also affected by the presence of additional risk factors, such as recent surgery, age over 35 years, high parity, high body mass index, smoking, and immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/16\">",
"     16",
"    </a>",
"    ]. The most important determinant of risk is a history of VTE in the patient or an affected first-degree relative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/17\">",
"     17",
"    </a>",
"    ]. In the case of FVL, a prior history of VTE may increase the likelihood of a VTE in pregnancy by 50-fold, from 0.2 percent to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with no personal or family history of thrombosis, the prevalence of selected thrombophilias and the probability of VTE during pregnancy based on retrospective studies are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76397 \" href=\"UTD.htm?22/49/23325\">",
"     table 1",
"    </a>",
"    ). Several prospective studies have reported a lower association with maternal thrombosis than observed in retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 4885 low-risk women with first trimester singleton pregnancy and no history of thromboembolism, 134 (2.7 percent) carried the FVL mutation and none had a thromboembolic event during pregnancy or up to six weeks postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study tested 1707 Australian nulliparous women with no prior history of adverse pregnancy outcome or personal or family history of VTE for FVL, PGM, MTHFR C677T and A1298C polymorphisms, and a thrombomodulin polymorphism prior to 22 weeks of gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/19\">",
"       19",
"      </a>",
"      ]. The prevalence of heterozygosity for FVL and PGM and homozygosity for the thrombomodulin polymorphism was 5.39, 2.38, and 3.51 percent, respectively, and none of the patients developed VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these studies were underpowered to rule out an association between FVL and VTE, they underscore the low risk of thrombosis in asymptomatic (no prior VTE) carriers of the mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898279\">",
"    <span class=\"h2\">",
"     Obstetrical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unlikely that inherited thrombophilia is a major factor in most adverse pregnancy outcomes. Multiple studies have evaluated the association between thrombophilias and adverse pregnancy outcomes; there are few data on fibrinolytic inhibitors. Although retrospective studies suggested a modest link between FVL heterozygosity (and possibly PGM heterozygosity and protein C and S deficiency) and fetal loss after 10 weeks and particularly for nonrecurrent loss after 20 weeks, most prospective studies have not found an association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. This suggests that any association is limited to high-risk populations and is modest. Small case-control or retrospective cohort studies involving heterogeneous populations have frequently reported contradictory results, in part because of the influence of various confounders that are often not analyzed appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Publication bias also likely plays a role. No rigorously performed, placebo-controlled, randomized clinical trials have been performed in women with inherited thrombophilia and history of fetal loss to support or refute the use of anticoagulation for preventing recurrent fetal losses in these women.",
"   </p>",
"   <p>",
"    Specific obstetrical complications are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898286\">",
"    <span class=\"h3\">",
"     Spontaneous abortion, fetal loss and stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large and contradictory body of literature on the association between maternal inherited thrombophilia and recurrent spontaneous abortion, fetal loss, and stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18,21-23,27-32\">",
"     18,21-23,27-32",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 31 case-control, cohort, and cross-sectional studies calculated pooled odds ratios (OR) with 95% CI by random effects models [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/27\">",
"       27",
"      </a>",
"      ]. Major findings included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      FVL was associated with early (before 13 weeks) (OR 2.01, 95% CI 1.13-3.58) and late (after 22 weeks) (OR 7.83, 95% CI 2.83-21.7) recurrent fetal loss, and late (after 19 weeks) non-recurrent fetal loss (OR 3.26, 95% CI 1.82-5.83).",
"     </li>",
"     <li>",
"      The PGM was linked to early recurrent (OR 2.56, 95% CI 1.04-6.29) and late nonrecurrent (OR 2.30, 95% CI 1.09-4.87) fetal loss.",
"     </li>",
"     <li>",
"      Protein S deficiency was associated with late non-recurrent fetal loss (OR 7.39, 95% CI 1.28-42.6), but an association with recurrent fetal loss was less clear (OR 14.7, 95% CI 0.99-218).",
"     </li>",
"     <li>",
"      Protein C and AT deficiencies were not significantly associated with fetal loss; however, sample sizes for these disorders were quite small.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Prospective Cohort on Thrombophilia (EPCOT) evaluated 843 women with thrombophilia, 571 of whom had 1524 pregnancies compared with 541 control women, 395 of whom had 1019 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/28\">",
"       28",
"      </a>",
"      ]. They defined miscarriage as a fetal loss less than 28 weeks of gestation and stillbirth as a fetal loss &gt;28 weeks of gestation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rate of fetal loss was increased in women with thrombophilia (29.4 versus 23.5 percent, OR 1.35, 95% CI 1.01-1.82).",
"     </li>",
"     <li>",
"      However, the OR was statistically significant only for stillbirth (OR 3.6, 95% CI 1.4-9.4 for stillbirth; versus OR 1.27, 95% CI 0.94-1.71 for miscarriage).",
"     </li>",
"     <li>",
"      The OR for stillbirth in women with multiple thrombophilias was 14.3 (95% CI 2.4-86.0), suggesting a dose-response effect.",
"     </li>",
"     <li>",
"      The ORs for stillbirth for individual defects were: AT deficiency 5.2 (95% CI 1.5-18.1), protein C deficiency 2.3 (95% CI 0.6-8.3), protein S deficiency 3.3 (95% CI 1.0-11.3), and FVL 2.0 (95% CI 0.5-7.7).",
"     </li>",
"     <li>",
"      In contrast to the association between thrombophilia and \"late\" fetal loss, there was no statistically significant association between either thrombophilias in general or specific thrombophilic defects (eg, multiple defects, PGM, protein C or S deficiency, FVL) and miscarriage; the only exception was AT deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are clear differences in the definition of losses between the meta-analysis and the EPCOT study, both show a stronger association between thrombophilias and late, rather than early, pregnancy losses.",
"   </p>",
"   <p>",
"    Subsequent to these analyses, the specific association between FVL and PGM and late pregnancy loss was highlighted by two case-control studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined 5001 pregnant women and found that FVL had a significant association with stillbirth (OR 10.9; 95% CI 2.07- 56.94), but not early fetal loss (OR 1.76; 95% CI 0.85-3.65) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/29\">",
"       29",
"      </a>",
"      ]. Neither the odds ratios for PGM and stillbirth nor PGM and early fetal loss reached statistical significance.",
"     </li>",
"     <li>",
"      The other study examined 102 consecutive women with pregnancy loss, 47 of whom experienced stillbirth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/30\">",
"       30",
"      </a>",
"      ]. There was a significant association between stillbirth and both FVL and PGM, but the association between recurrent early pregnancy loss and FVL and PGM was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This link to late, but not early, pregnancy loss was confirmed in a cohort study of 491 patients with thrombophilias and late pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients were tested for the presence of activated protein C resistance, FVL and PGM, hyperhomocysteinemia, deficiencies of AT, protein C and S and both anticardiolipin antibodies and lupus anticoagulants. The presence of one or more maternal thrombophilias was protective of recurrent losses at &lt;10 weeks (OR 0.55, 95% CI 0.33-0.92 for one and OR 0.48, 95% CI 0.29-0.78 for multiple thrombophilias, respectively). In contrast, the presence of one or more maternal thrombophilias was associated with an increased risk of losses &gt;10 weeks (OR 1.76, 95% CI 1.05-2.94 for one and OR 1.66, 95% CI 1.03-2.68 for multiple thrombophilias, respectively). In addition, women who experienced only euploid first trimester losses were not more likely to have an identified thrombophilia than women who experienced only aneuploid losses (OR 1.03, 95% CI 0.38-2.75). Maternal thrombophilia(s) was associated with an increased risk of fetal loss after 14 weeks (OR 3.41, 95% CI 1.9-6.1 for one and OR 3.86, 95% CI 2.26-6.59 for multiple thrombophilias, respectively).",
"   </p>",
"   <p>",
"    This paradoxical observation that maternal thrombophilias are protective of early loss is not unexpected. Early pregnancy is normally associated with a low oxygen environment (oxygen pressures of",
"    <span class=\"nowrap\">",
"     17+/-",
"    </span>",
"    6.9 mm Hg and 60.7",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    8.5 mm Hg at 8 to 10 and 13 weeks of gestation, respectively), trophoblast plugging of the intervillous space, and low Doppler flow of the uteroplacental circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Oxygen may actually be harmful during the embryonic period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, the adverse effect of maternal thrombophilias on uteroplacental blood flow and oxygen delivery would be expected to be harmful to the late, but not early, first trimester pregnancy.",
"   </p>",
"   <p>",
"    On the other hand, most [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-23\">",
"     18-23",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/28,32\">",
"     28,32",
"    </a>",
"    ], large prospective studies have found no association between fetal loss and inherited thrombophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898294\">",
"    <span class=\"h3\">",
"     Fetal growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There does not appear to be a consistent link between thrombophilia and fetal growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-23,36,37\">",
"     18-23,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that evaluated the relationship between fetal growth restriction and homozygous or heterozygous FVL (12 case-control and 4 cohort studies), homozygous or heterozygous PGM (11 case-control studies), and MTHFR C677T homozygosity (10 case-control and 2 cohort studies) found no to weak evidence of an association between any of these thrombophilias and growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/36\">",
"     36",
"    </a>",
"    ]. Strengths of this analysis were that only studies that met strict criteria were included and analyzed by a random effects model to account for heterogeneity, and publication bias was taken into account. The association reported in case-control studies appeared to be due to publication bias.",
"   </p>",
"   <p>",
"    Meta-analysis has suggested a link between protein S deficiency and fetal growth restriction (OR 10.2; 95% CI 1.1&ndash;91.0), but not with protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the number of patients available was very small, resulting in wide confidence intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898301\">",
"    <span class=\"h3\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The weight of current evidence suggests that hereditary thrombophilia is not associated with an increased risk of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-23\">",
"     18-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meta-analyses of the link between FVL and preeclampsia have generally found a small increased risk of preeclampsia among carriers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/25,26,38-40\">",
"       25,26,38-40",
"      </a>",
"      ]. However, this could be related to publication and selection bias of the included studies. Prospective studies do not show an association [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of studies have failed to demonstrate an association between the PGM and preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/19,23,29,39,41-43\">",
"       19,23,29,39,41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, meta-analysis has also suggested a link between protein S and C deficiency and",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia",
"      </span>",
"      (OR 12.7; 95% CI 4&ndash;39.7 and OR 21.5; 95% CI 1.1&ndash;414.4, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/37\">",
"       37",
"      </a>",
"      ]. Again, the inclusion of multiple small heterogeneous studies undermines confidence in this association.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898309\">",
"    <span class=\"h3\">",
"     Abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consistent association between any thrombophilia and placental abruption has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18-23,37\">",
"     18-23,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperhomocysteinemia (fasting level greater than 15",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/44\">",
"     44",
"    </a>",
"    ], but not gene MTHFR polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/45\">",
"     45",
"    </a>",
"    ], may be associated with recurrent abruption. Total plasma homocysteine concentration should be measured in a fasting state using sensitive assays. Although there is no widely accepted threshold for diagnosing hyperhomocysteinemia in pregnant women, a value greater than 15",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    is reasonable in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898317\">",
"    <span class=\"h2\">",
"     Fetal thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal carriage of thrombophilic mutations may also have adverse clinical consequences, such as pregnancy loss, growth restriction, preterm birth, perinatal stroke, and cerebral palsy, but these reports included only a few affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/46-51\">",
"     46-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898324\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS FOR TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine testing for inherited thrombophilias in unselected populations is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of the low frequency of the condition becoming symptomatic and the lack of a safe, cost-effective, long-term method of prophylaxis against thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/16,52\">",
"     16,52",
"    </a>",
"    ]. Furthermore, there is no strong evidence on which to base recommendations regarding whom to test or the optimal panel of tests. The American College of Obstetricians and Gynecologists (ACOG) suggests screening for thrombophilia when the results will affect",
"    <span class=\"nowrap\">",
"     pregnancy/postpartum",
"    </span>",
"    management, and suggests avoiding screening when treatment is indicated because of patient-specific risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'When not to screen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, screening is appropriate in women with a nonrecurrent risk factor, such as femoral fracture, surgery, or prolonged immobilization because those with no hereditary thrombophilic defect are at low risk for thrombosis and do not require antepartum thromboprophylaxis, whereas those with a thrombophilic defect are at higher risk of VTE during pregnancy; the magnitude of risk and management depend on the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/54\">",
"     54",
"    </a>",
"    ]. Women with a past history of idiopathic (unprovoked) or recurrent VTE are at relatively high risk of recurrent thrombosis and should receive thromboprophylaxis antepartum regardless of thrombophilia status. For women with a prior VTE associated with estrogen-progestin contraceptive use or pregnancy, we would recommend prophylactic anticoagulation whether or not a thrombophilic defect is identified. Nevertheless, we would screen such women for hereditary thrombophilia, particularly if there was a family history of VTE. If a high-risk thrombophilic defect such as antithrombin deficiency was identified, treatment with higher-intensity prophylactic anticoagulation (eg, more than a single daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg subcutaneously) and antithrombin concentrate in the peripartum period would be reasonable.",
"   </p>",
"   <p>",
"    Testing is also reasonable in asymptomatic (no prior VTE) women planning a pregnancy who have a first degree relative with VTE before age 50 years or a history of a high-risk thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53\">",
"     53",
"    </a>",
"    ]. Identification of a heritable thrombophilic defect in the relative can narrow the laboratory evaluation to determine whether or not the woman carries the specific defect. The rationale for such testing is that ante- and postpartum prophylaxis may be indicated if the asymptomatic patient is found to be a carrier of one of the more highly thrombogenic defects (eg, antithrombin deficiency, double heterozygosity or homozygosity for FVL and PGM). Postpartum thromboprophylaxis may be indicated if the asymptomatic patient is a carrier of one of the less thrombogenic defects (eg, heterozygous FVL) in the presence of other risk factors (eg, cesarean section, prolonged immobilization) or has a symptomatic first degree relative with VTE before age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53,55,56\">",
"     53,55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, screening women with a history of recurrent or nonrecurrent early fetal loss, abruption, intrauterine growth restriction, or preeclampsia is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of lack of evidence of a causal association",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of evidence that administration of anticoagulant drugs is effective in improving pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53,56\">",
"     53,56",
"    </a>",
"    ]. Testing women with a history of recurrent or non-recurrent unexplained fetal loss",
"    <strong>",
"     after",
"    </strong>",
"    10 weeks of gestation associated with histological evidence of placental ischemia and infarction and maternal vessel thrombosis is controversial since the recurrence risk is relatively low and there are no high-quality, placebo-controlled, randomized clinical trials to establish the efficacy of anticoagulation for preventing recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898332\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898340\">",
"    <span class=\"h2\">",
"     When to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of tests that can be performed when evaluating for inherited thrombophilias. Ideally, laboratory testing is performed remote (at least six weeks) from the thrombotic event and while the patient is not pregnant and not taking anticoagulation or hormonal therapy, for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      induces a decline in AT levels and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      decreases protein C and protein S concentrations, making interpretation of results difficult.",
"     </li>",
"     <li>",
"      Pregnancy is associated with increased resistance to activated protein C (APC) in \"first generation\" assays, due to increased factor VIII levels and decreased protein S levels. While modifications in the endpoint of the functional assay for activated protein resistance can render it usable in pregnant patients for ascertaining the presence of FVL, false positive laboratory results are not uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Most clinical laboratories that perform APC resistance assays currently use \"second generation\" tests.",
"     </li>",
"     <li>",
"      The levels of free and total protein S are significantly reduced in normal pregnancy, and a clear threshold for diagnosis of protein S deficiency has not been established [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/3,59\">",
"       3,59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898348\">",
"    <span class=\"h2\">",
"     Test panel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for inherited thrombophilias should include evaluation for FVL mutation, PGM, and AT, protein C, and protein S deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53\">",
"     53",
"    </a>",
"    ]. We recommend the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AT deficiency. The AT-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      cofactor assay will detect all subtypes of familial AT deficiency and is therefore the best single laboratory screening test for this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Activated protein C resistance and FVL. APC resistance can be assessed using a second generation coagulation assay. Patients with low APC resistance ratios should then be genotyped for the FVL mutation. Alternatively, patients can directly undergo genotyping for FVL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein S deficiency. Protein S should be assessed initially by performing a functional assay remote from the time of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link&amp;anchor=H10#H10\">",
"       \"Protein S deficiency\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, levels of total or free protein S antigen &lt;65",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      are considered to be in the deficient range [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/60\">",
"       60",
"      </a>",
"      ]. However, in a prospective family cohort study involving 1143 relatives with various thrombophilic defects, only young relatives with free protein S levels less than the 5th percentile (&lt;41",
"      <span class=\"nowrap\">",
"       IU/dL)",
"      </span>",
"      or less than the 2.5th percentile (&lt;33",
"      <span class=\"nowrap\">",
"       IU/dL)",
"      </span>",
"      were at higher risk of a first venous thrombosis compared with those in the upper quartile (&gt;91",
"      <span class=\"nowrap\">",
"       IU/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Protein C deficiency. Functional assays are usually performed by amidolytic methods using a snake venom to activate protein C; functional assays using a clotting endpoint are also available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H17#H17\">",
"       \"Protein C deficiency\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PGM using PCR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, these patients should be tested for thrombophilia associated with antiphospholipid syndrome, which is an acquired thrombophilia. Women with a history of fetal loss may also benefit from diagnosis of antiphospholipid syndrome, as treatment may improve pregnancy outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend measurement of homocysteine levels as part of the thrombophilia evaluation. In the United States population, homocysteine levels have come down since folate fortification of flour was mandated; thus, fewer patients with VTE are found to have high homocysteine levels. Furthermore, pregnant women are routinely prescribed multivitamins containing folate to reduce the risk of neural tube defects. In addition, recent data show that high homocysteine levels are a weaker risk factor for VTE or arterial thrombosis than reported in earlier studies (OR 1.2-1.6 versus 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/61\">",
"     61",
"    </a>",
"    ], and intervention studies with B vitamin supplementation, albeit in nonpregnant patients, do not show a reduction in arterial or venous thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also do not recommend testing for MTHFR polymorphisms (C677T, 1298C). Homozygosity for these genetic variants is a relatively common cause of mildly elevated plasma homocysteine levels in the general population, often occurring in association with serum folate levels in the low normal range. High quality epidemiologic studies (eg, Leiden Thrombophilia Study, Physicians' Health Study) have not found a significant increase in VTE risk among individuals homozygous for MTHFR polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Data that MTHFR polymorphisms do not carry any risk in pregnancy are less definitive, but clearly trend that way [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of the PAI-1 polymorphism",
"    <span class=\"nowrap\">",
"     (4G/5G)",
"    </span>",
"    is very high (approximately 50 percent) in the general population and 20 to 25 percent of these individuals are homozygous for the purported",
"    <span class=\"nowrap\">",
"     4G/4G",
"    </span>",
"    \"thrombogenic\" genotype. The latter is associated with a two- to three-fold elevation in PAI-1 levels, and these levels can be even higher in patients with metabolic syndrome and those with the",
"    <span class=\"nowrap\">",
"     D/D",
"    </span>",
"    genotype in the ACE gene. In our opinion, the available studies linking these genotypes with preeclampsia and other adverse pregnancy outcomes have many limitations and do not provide any evidence for testing women with adverse pregnancy outcome or using the results of prior testing to influence patient management. We therefore strongly recommend that these tests not be ordered in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898355\">",
"    <span class=\"h1\">",
"     PREVENTION OF VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898363\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is prevention of maternal VTE. Based on the data cited in the discussion above, as well as indirect evidence from studies in nonpregnant individuals, we agree with the approach described by the American College of Obstetricians and Gynecologists (ACOG) tables (",
"    <a class=\"graphic graphic_table graphicRef56377 \" href=\"UTD.htm?39/35/40508\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69149 \" href=\"UTD.htm?19/8/19597\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35472870\">",
"    <span class=\"h3\">",
"     Women with high-risk thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and ACOG suggest that women with high-risk thrombophilia (AT deficiency, homozygotes for the FVL mutation, homozygotes for the PGM mutation, double heterozygotes for FVL and PGM) receive anticoagulation antepartum and postpartum, whether or not they have a personal or family history of VTE (",
"    <a class=\"graphic graphic_table graphicRef69149 \" href=\"UTD.htm?19/8/19597\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The American College of Chest Physicians guideline takes personal and family history into account in managing these patients. For women with high-risk thrombophilias (homozygotes for the FVL mutation, homozygotes for the PGM mutation) and no personal history of VTE, they recommend only postpartum anticoagulation if there is no family history of VTE, but both antepartum and postpartum anticoagulation if there is a positive family history of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35472877\">",
"    <span class=\"h4\">",
"     Women with lower-risk thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with lower-risk thrombophilias (heterozygotes for FVL and PGM, protein C or S deficiency) depends upon their personal and family history of thrombotic events, as well as other standard VTE risk factors.",
"   </p>",
"   <p>",
"    Women with lower-risk thrombophilias (heterozygotes for FVL and PGM, protein C or S deficiency) and a single prior VTE episode are at increased risk of pregnancy-related thrombosis and should receive antepartum and postpartum anticoagulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 23 female carriers of thrombophilic mutations with a personal and family history of thrombosis reported that the overall risk of",
"      <strong>",
"       recurrent",
"      </strong>",
"      VTE related to pregnancy was 26 percent per patient-year of observation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/70\">",
"       70",
"      </a>",
"      ]. VTE occurred in 7 of 28 (25 percent) pregnancies managed without prophylactic anticoagulation and in 1 of 12 pregnancies of women treated with anticoagulants.",
"     </li>",
"     <li>",
"      In another series of 25 women with thrombophilia and a history of one previous unprovoked or idiopathic VTE, there were four recurrences (two antepartum and two postpartum) despite postpartum anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, asymptomatic women (no prior VTE) with lower-risk thrombophilias do not routinely require antepartum anticoagulation whether or not they have a family history of VTE, but should undergo individualized risk assessment and monitoring for clinical signs and symptoms of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/18,53,55,56,71,72\">",
"     18,53,55,56,71,72",
"    </a>",
"    ]. In the absence of other major risk factors for VTE, their risk of thromboembolism is likely less than 1 percent.",
"   </p>",
"   <p>",
"    There is no strong evidence that postpartum prophylaxis is necessary in asymptomatic women with lower-risk thrombophilias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ]. Because the risk of postpartum thrombosis in the absence of other risk factors is quite low, ACOG suggests surveillance without anticoagulation therapy or initiating prophylaxis postpartum if there are additional risk factors for thrombosis (eg, cesarean delivery, obesity, prolonged immobility, first degree family member with VTE before age 50) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/53\">",
"     53",
"    </a>",
"    ]. The ACCP recommends postpartum anticoagulation for women with lower-risk thrombophilias if there is a positive family history of VTE; clinical vigilance without anticoagulation is adequate if there is no family history of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ]. The RCOG recommends seven days postpartum thromboprophylaxis, but six weeks thromboprophylaxis if the patient has a family history of VTE or other risk factors for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link&amp;anchor=H4#H4\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\", section on 'Postpartum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898370\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation should be initiated in the first trimester since the risk of VTE is increased early in pregnancy. Postpartum risk of VTE is as high or higher than antepartum risk, so postpartum treatment dosing regimens should be as or more aggressive than antepartum regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898424\">",
"    <span class=\"h3\">",
"     Stage of pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20962219\">",
"    <span class=\"h4\">",
"     Antepartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, LMWH or adjusted-dose unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is used for anticoagulation because the efficacy and safety for the fetus have been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/74\">",
"     74",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    , by comparison, crosses the placenta and has been associated with embryopathy and fetal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulation during pregnancy\", section on 'Warfarin'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    LMWH administered by the subcutaneous route is an attractive alternative to unfractionated heparin because of its better bioavailability, longer half-life, and ease of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. LMWH has become the",
"    <strong>",
"     anticoagulant of choice",
"    </strong>",
"    for thromboprophylaxis and treatment of thromboembolism in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55,76,77\">",
"     55,76,77",
"    </a>",
"    ]. Unfractionated heparin is an acceptable, and less expensive, alternative to LMWH, but can produce demonstrable maternal bone loss when taken for prolonged intervals. Low molecular weight (LMW) heparins may have less of an adverse effect on bone than unfractionated heparin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H4#H4\">",
"     \"Drugs that affect bone metabolism\", section on 'Heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20962227\">",
"    <span class=\"h4\">",
"     Intrapartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation during labor should be avoided except in the highest risk settings. Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is discontinued when labor begins or 24 to 36 hours before induction of labor or scheduled cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Ideally, LMWH should be stopped at 36 to 37 weeks of gestation, or earlier in the event of threatened preterm birth, and replaced with unfractionated heparin to minimize the risk of epidural hematoma from regional anesthesia. At a minimum, LMWH should be stopped at least 24 hours before induction of labor, cesarean delivery, or placement of neuraxial anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ]. The use of neuraxial anesthesia in patients who have recently received anticoagulants is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12561180#H12561180\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Neuraxial analgesia and the anticoagulated patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20962235\">",
"    <span class=\"h4\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum, oral anticoagulant therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be initiated and is compatible with breastfeeding.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is resumed at prophylactic doses 6 to 12 hours after cesarean delivery and 4 to 6 hours after vaginal delivery (if no significant bleeding) and should be continued concurrently with oral anticoagulants for the initial four days",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    48 hours after the woman has reached an appropriate INR (ie, 2.0 to 3.0) on such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Anticoagulation (LMWH or oral anticoagulants) should be continued for at least six weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the duration of therapy depends upon the site of thromboembolism and risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Use of warfarin, unfractionated heparin, or LMWH is compatible with breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Estrogen containing contraceptives are generally contraindicated in women with inherited thrombophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=see_link\">",
"     \"Contraception for women with inherited thrombophilias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898432\">",
"    <span class=\"h3\">",
"     Dose and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose and duration of anticoagulation therapy in pregnancy are uncertain since appropriately designed clinical trials have not yet been performed. The various drug regimens are described in the table (",
"    <a class=\"graphic graphic_table graphicRef56377 \" href=\"UTD.htm?39/35/40508\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27471887\">",
"    <span class=\"h4\">",
"     Therapeutic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This refers to unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing to keep the activated partial thromboplastin time in the therapeutic range, or therapeutically equivalent dosing of LMWH.",
"    <strong>",
"     &nbsp;",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &mdash; Adjusted dose heparin is administered every 12 hours by subcutaneous injection. The dose should be adjusted to maintain the six-hour postinjection activated partial thromboplastin time (aPTT) at 1.5 to 2.5 times the mean of the control value or the patient's baseline aPTT value. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"       \"Clinical use of coagulation tests\"",
"      </a>",
"      .) Ice applied to the proposed injection site for 20 minutes prior to the injection will help to minimize bruising.",
"      <br/>",
"      <br/>",
"      Calcium supplementation (1500 mg in divided doses daily) and weight bearing exercise (eg, walking) are recommended for women taking heparin to minimize the osteopenic effects of this drug. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"       \"Drugs that affect bone metabolism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In some patients, unfractionated heparin will need to be given every eight hours to avoid an excessive volume (more than 2 mLs) of medication in the injection.",
"     </li>",
"     <li>",
"      LMWH &mdash; Therapeutic doses of LMWH based on body weight are usually administered every 12 hours by subcutaneous injection. Our preference is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours. Although data supporting the need for laboratory monitoring are sparse [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/78-80\">",
"       78-80",
"      </a>",
"      ], some experts suggest monitoring anti-Xa levels in high-risk pregnant women treated with therapeutic doses of LMWH. The goal with twice daily administration of LMWH is to achieve anti-factor Xa levels of 0.6 to 1.0",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      four hours after injection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27471903\">",
"    <span class=\"h4\">",
"     Prophylactic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic anticoagulation uses lower doses of anticoagulants, which reduce both the degree of anticoagulation and the risk of bleeding complications. Laboratory monitoring is not required. However, low or prophylactic dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may not be adequate in women at high risk of VTE. In a retrospective cohort study including 34 women (44 pregnancies) at intermediate risk of VTE who received low-dose LMWH for six weeks postpartum and 57 women (82 pregnancies) at high risk of VTE who received both antepartum and postpartum low-dose LMWH, all VTE events occurred in high-risk patients (postpartum incidence of 7.0 percent, 95% CI 2.9&ndash;16.7; antepartum incidence 1.8 percent, 95% CI, 0.4&ndash;9.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/81\">",
"     81",
"    </a>",
"    ]. The authors concluded that low-dose LMWH prophylaxis may not be sufficient in high-risk patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &mdash; Subcutaneous heparin, 5000 units administered every 12 hours, is one option [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]. An acceptable alternative dose-based regimen is every 12-hour injections of 5000 to 7500 units in the first trimester, 7500 to 10,000 units in the second trimester, and 10,000 units in the third trimester (reduce if the aPTT is elevated) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LMWH &mdash; The dose depends on the specific agent, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      5000 U subcutaneously or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      40 mg subcutaneously every 24 hours (adjusted for extremes of body weight). Monitoring of prophylactic LMWH therapy using anti-factor Xa levels is not required. A regimen that one of us (KB) frequently uses for intermediate-risk women as pregnancy progresses is enoxaparin up to a maximal dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily. I (KB) may start at 40 mg and gradually increase the dose as the patient&rsquo;s weight increases. This likely provides a higher dose, but still with only a single daily injection, which is better tolerated than twice daily injections for many months. The efficacy of prophylaxis has been studied by Roeters, et al [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/81\">",
"       81",
"      </a>",
"      ]. They conducted a retrospective cohort study of 34 women having 44 pregnancies who were at intermediate risk of VTE and who received low-dose LMWH for 6 weeks postpartum and 57 women having 82 pregnancies who were with a high VTE risk who received both antepartum and postpartum low-dose LMWH. All VTE events occurred in high-risk patients with a postpartum incidence of 7.0 percent (95% CI, 2.9&ndash;16.7) and antepartum incidence of 1.8 percent (95% CI, 0.4&ndash;9.2). The authors concluded that low-dose LMWH prophylaxis may not be sufficient in high-risk patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27471911\">",
"    <span class=\"h4\">",
"     Intermediate dose anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third option is intermediate-dose anticoagulation with either LMWH or unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . This provides a level of anticoagulation that is intermediate between prophylactic and adjusted-dose regimens.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &mdash; Intermediate-dose unfractionated heparin is given subcutaneous every 12 hours in doses adjusted to achieve anti-factor Xa levels of 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      six hours after the injection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LMWH &mdash; Intermediate-dose LMWH depends on the specific agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      5000 units subcutaneously every 12 hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      40 mg subcutaneously every 12 hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898454\">",
"    <span class=\"h3\">",
"     Risk of bleeding and reversal of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of studies of the safety of LMWH when used in pregnancy for any indication (64 studies, 2777 pregnancies), significant maternal bleeding occurred in 55 pregnancies (1.98 percent; 95% CI 1.5-2.57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/85\">",
"     85",
"    </a>",
"    ]. Bleeding occurred antepartum in 12 women (0.43 percent; 95% CI 0.22-0.75 percent), was delivery-related in 26 women (0.94 percent; 95% CI 0.61-1.37 percent), and resulted in wound hematoma in 17 postpartum women (0.61 percent; 95% CI 0.36-0.98 percent). The indication for LMWH was thromboprophylaxis in 1321 pregnancies, prevention of adverse pregnancy outcome in 447 pregnancies, treatment in 174 pregnancies, and unspecified in the remainder.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     Protamine sulfate",
"    </a>",
"    can be used for rapid reversal of anticoagulation in women who have significant bleeding or at risk of delivery related bleeding. The regimen is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin reversal with protamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H33#H33\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Bleeding and protamine reversal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antithrombin concentrates are available for patients with AT deficiency, but should be reserved for use during labor, delivery, or obstetric complications where the risks of bleeding from anticoagulation are unacceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898461\">",
"    <span class=\"h1\">",
"     MATERNAL SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weekly assessment of the patient's platelet count during the first two weeks of unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy and monthly thereafter, given the potential for heparin-induced thrombocytopenia. Patients on LMWH can just have their platelet counts checked monthly because the risk of thrombocytopenia is lower. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Education regarding the signs and symptoms of thromboembolic disease. Classic symptoms of deep vein thrombosis (DVT) include swelling, pain, and discoloration in the involved extremity, usually the left leg. There is not necessarily a correlation between the location of symptoms and the site of thrombosis. Symptoms in the calf alone are often the presenting manifestation of significant proximal vein involvement, while some patients with whole leg symptoms are found to have isolated calf vein DVT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898468\">",
"    <span class=\"h1\">",
"     PREVENTION OF PREGNANCY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence does not support an association between inherited thrombophilia and preeclampsia, fetal growth restriction, or abruption, and, in turn, it does not support prophylactic anticoagulation to prevent preeclampsia, fetal growth restriction, or abruption in women with inherited thrombophilias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, there is some evidence of an association between inherited thrombophilia and late fetal loss. Although data are insufficient to establish the value or lack of value of prophylactic anticoagulation for improving pregnancy outcome in these patients, given the possibility of benefit, anticoagulation can be considered on a case-by-case basis after taking into account the patient's medical and obstetrical history, placental histopathology, and other potential causes of the adverse pregnancy outcome. For example, was there a medical or obstetrical disorder that could account for the pregnancy loss (eg, poorly controlled diabetes, aneuploidy, uterine anomaly, fetal anomaly, fetal infection)? Was the mother exposed to trauma or a teratogen, which could have led to the pregnancy loss? If these and other causes of fetal loss can be excluded and placental histology shows extensive evidence of thrombotic lesions, one of us (KB) would consider anticoagulation during pregnancy. The care of these rare patients is complex and should involve a maternal fetal medicine specialist and hematologist.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French trial carried out by Gris, et al [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/86\">",
"       86",
"      </a>",
"      ] involved 160 women who were heterozygous for the FVL or PGM or with protein S deficiency who had one unexplained pregnancy loss at or after 10 weeks of gestation. All were given 5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      &nbsp;daily before conception to eliminate confounding from hyperhomocysteinemia and one-half were given either low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(100 mg daily) or LMWH (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      &nbsp;40 mg subcutaneously daily) from 8 to 37 weeks of gestation.",
"      <br/>",
"      <br/>",
"      Women treated with enoxaparin&nbsp;had a higher live birth rate than those treated with low-dose aspirin: 86.3 percent",
"      <span class=\"nowrap\">",
"       (69/80)",
"      </span>",
"      versus 28.8 percent",
"      <span class=\"nowrap\">",
"       (23/80)",
"      </span>",
"      (OR 15.5, 95% CI 7-34). Enoxaparin was superior to low-dose aspirin in each subgroup defined according to the underlying constitutional thrombophilic disorder. Use of enoxaparin was also associated with significantly higher birth weights and a lower frequency of fetal growth restriction compared to treatment with low-dose aspirin. Two concerns with this trial are absence of blinding and the lower than expected loss rate in the aspirin-only group.",
"     </li>",
"     <li>",
"      The possible benefits of anticoagulation were also demonstrated in a British cohort study of women with known AT, protein S deficiency or protein C deficiency and their female relatives [",
"      <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/87\">",
"       87",
"      </a>",
"      ]. Unfractionated or LMWH was started as soon as pregnancy was diagnosed. Women on thromboprophylaxis had significantly fewer fetal losses (&gt;22 weeks of gestation) than untreated women",
"      <span class=\"nowrap\">",
"       (0/26",
"      </span>",
"      compared to",
"      <span class=\"nowrap\">",
"       5/11).",
"      </span>",
"      The clinical significance of this finding is limited, given that the study was small, unblended, and not randomized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other randomized trials have evaluated whether LMWH prevents fetal loss, but the dramatic benefit seen in the aforementioned trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/86,87\">",
"     86,87",
"    </a>",
"    ] was not replicated. However, these other trials differed greatly with respect to inclusion criteria, particularly the timing of pregnancy loss and the presence or absence of a thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/72,88-92\">",
"     72,88-92",
"    </a>",
"    ]. A systematic review of these trials found that use of LMWH for the prevention of early recurrent or late nonrecurrent pregnancy loss showed a trend toward increased live birth rates with therapy (range of live births with LMWH 81 to 95 percent; without LMWN, 29 to 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/93\">",
"     93",
"    </a>",
"    ]. However, the observed statistical and clinical heterogeneity across the studies led the authors to conclude that there was insufficient evidence to support the routine use of LMWH to improve pregnancy outcomes in women with inherited thrombophilia and a history of pregnancy loss. While there are also small, observational studies suggesting a benefit from antithrombotic therapy, these studies suffer from lack of an appropriate control group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, two large randomized trials found that neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone nor aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    improved the live-birth rate of women with unexplained recurrent pregnancy loss before 20 or 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/5/26714/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Some of these women (6 percent in one study, 13 percent in the other) had one or more inherited thrombophilias. A limitation of these trials is that they did not differentiate between early and late fetal loss and most of the women did not have an inherited thrombophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20962302\">",
"    <span class=\"h2\">",
"     Fetal surveillance and timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that there may be a small increased risk of stillbirth in thrombophilic pregnant women who are receiving or not receiving prophylactic anticoagulation,&nbsp;we suggest weekly fetal assessment with nonstress tests beginning at &ge;36 weeks of gestation and delivery at 39 weeks of gestation in the absence of an obstetrical complication such as preeclampsia, abruption, or fetal growth restriction. For women who have been anticoagulated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should be discontinued before scheduled delivery. (See",
"    <a class=\"local\" href=\"#H20962227\">",
"     'Intrapartum'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If obstetrical complications are present, fetal surveillance should be initiated earlier and delivery timed to optimize maternal and neonatal outcomes. (See specific topic reviews on obstetrical complications).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       \"Patient information: Factor V Leiden (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898475\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with inherited thrombophilias are at higher risk of thromboembolic complications during pregnancy because of pregnancy-associated changes in several coagulation factors. (See",
"      <a class=\"local\" href=\"#H7898243\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of selected thrombophilias and the probability of venous thromboembolism (VTE) during pregnancy in women with no personal or family history of thrombosis are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef76397 \" href=\"UTD.htm?22/49/23325\">",
"       table 1",
"      </a>",
"      ). The risk of thromboembolism is higher in carrier women with a personal history or strong family history of thromboembolic events. (See",
"      <a class=\"local\" href=\"#H7898272\">",
"       'Maternal venous thromboembolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies have reported an association between some types of thrombophilia and adverse pregnancy outcomes, but the absolute risk is small and varies considerably among reports. Most large, prospective cohort studies have failed to establish a consistent association between inherited thrombophilias and adverse pregnancy outcomes in low-risk populations. (See",
"      <a class=\"local\" href=\"#H7898279\">",
"       'Obstetrical complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening for thrombophilia when the results will affect management decisions and avoiding screening when treatment is indicated because of patient specific risk factors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate candidates for screening include reproductive age women with a personal history of venous thrombosis associated with a nonrecurrent risk factor (such as femoral fracture, surgery, or prolonged immobilization) and asymptomatic women (no prior VTE) planning a pregnancy who have a first degree relative with VTE before age 50 or a history of a high-risk thrombophilia. Whenever possible, laboratory testing should be performed remote from the thrombotic event and while the patient is not pregnant and not taking anticoagulation or hormonal therapy. (See",
"      <a class=\"local\" href=\"#H7898324\">",
"       'Selection of patients for testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7898332\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for inherited thrombophilia in women with a history of recurrent or nonrecurrent fetal loss, abruption, intrauterine growth restriction, or preeclampsia is not recommended (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There is insufficient evidence of a causal association and insufficient evidence that administration of anticoagulant drugs is effective in improving pregnancy outcome. (See",
"      <a class=\"local\" href=\"#H7898324\">",
"       'Selection of patients for testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation of women with late fetal loss may be considered on a case-by-case basis after taking into account the patient's medical and obstetrical history, placental histopathology, and other potential causes of the late fetal loss. (See",
"      <a class=\"local\" href=\"#H7898468\">",
"       'Prevention of pregnancy complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898483\">",
"    <span class=\"h2\">",
"     Prevention of VTE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of treatment is prevention of maternal VTE. Based on the data cited in the discussion above, as well as indirect evidence from studies in nonpregnant individuals, we suggest the approach described in the tables (",
"      <a class=\"graphic graphic_table graphicRef56377 \" href=\"UTD.htm?39/35/40508\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69149 \" href=\"UTD.htm?19/8/19597\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7898370\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Obstetrical management",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of an obstetrical complication such as preeclampsia, abruption, or fetal growth restriction,&nbsp;we suggest weekly assessments with nonstress tests beginning at &ge;36 weeks of gestation and delivery at 39 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H20962302\">",
"       'Fetal surveillance and timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/1\">",
"      Lockwood CJ. Heritable coagulopathies in pregnancy. Obstet Gynecol Surv 1999; 54:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/2\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/3\">",
"      Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/4\">",
"      Kupferminc MJ, Yair D, Bornstein NM, et al. Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia. Stroke 2000; 31:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/5\">",
"      Rodger MA, Paidas M, McLintock C, et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008; 112:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/6\">",
"      Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/7\">",
"      Domagala TB, Adamek L, Nizankowska E, et al. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/8\">",
"      McColl MD, Ellison J, Reid F, et al. Prothrombin 20210 G--&gt;A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000; 107:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/9\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/10\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/11\">",
"      Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/12\">",
"      Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/13\">",
"      Jacobsen AF, Dahm A, Bergrem A, et al. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 2010; 8:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/14\">",
"      Folkeringa N, Brouwer JL, Korteweg FJ, et al. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol 2007; 138:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/15\">",
"      Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/16\">",
"      Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/17\">",
"      Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/18\">",
"      Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/19\">",
"      Said JM, Higgins JR, Moses EK, et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010; 115:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/20\">",
"      Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/21\">",
"      Clark P, Walker ID, Govan L, et al. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol 2008; 140:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/22\">",
"      Lindqvist PG, Svensson PJ, Marsa&aacute;l K, et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/23\">",
"      Silver RM, Zhao Y, Spong CY, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010; 115:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/24\">",
"      Kjellberg U, van Rooijen M, Bremme K, Hellgren M. Factor V Leiden mutation and pregnancy-related complications. Am J Obstet Gynecol 2010; 203:469.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/25\">",
"      Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/26\">",
"      Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003; 21:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/27\">",
"      Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/28\">",
"      Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/29\">",
"      Kocher O, Cirovic C, Malynn E, et al. Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. Am J Clin Pathol 2007; 127:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/30\">",
"      Sottilotta G, Oriana V, Latella C, et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thromb Res 2006; 117:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/31\">",
"      Roqu&eacute; H, Paidas MJ, Funai EF, et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/32\">",
"      Rodger MA, Betancourt MT, Clark P, et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7:e1000292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/33\">",
"      Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992; 80:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/34\">",
"      Jaffe R. Investigation of abnormal first-trimester gestations by color Doppler imaging. J Clin Ultrasound 1993; 21:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/35\">",
"      Watson AL, Skepper JN, Jauniaux E, Burton GJ. Susceptibility of human placental syncytiotrophoblastic mitochondria to oxygen-mediated damage in relation to gestational age. J Clin Endocrinol Metab 1998; 83:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/36\">",
"      Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. Obstet Gynecol 2009; 113:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/37\">",
"      Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/38\">",
"      Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/39\">",
"      Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/40\">",
"      Dudding T, Heron J, Thakkinstian A, et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 2008; 6:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/41\">",
"      D'Elia AV, Driul L, Giacomello R, et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Invest 2002; 53:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/42\">",
"      Morrison ER, Miedzybrodzka ZH, Campbell DM, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/43\">",
"      Kahn SR, Platt R, McNamara H, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol 2009; 200:151.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/44\">",
"      Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000; 71:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/45\">",
"      Nurk E, Tell GS, Refsum H, et al. Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004; 117:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/46\">",
"      von Kries R, Junker R, Oberle D, et al. Foetal growth restriction in children with prothrombotic risk factors. Thromb Haemost 2001; 86:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/47\">",
"      G&ouml;pel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999; 353:1411.",
"     </a>",
"    </li>",
"    <li>",
"     Schlembach, D, Beinder, E, Zingsem, J, et al. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci (Lond) 2003; 105:279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/49\">",
"      Dizon-Townson DS, Meline L, Nelson LM, et al. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/50\">",
"      Gibson CS, MacLennan AH, Hague WM, et al. Associations between inherited thrombophilias, gestational age, and cerebral palsy. Am J Obstet Gynecol 2005; 193:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/51\">",
"      Gibson CS, MacLennan AH, Janssen NG, et al. Associations between fetal inherited thrombophilia and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:947.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/52\">",
"      Clark P, Twaddle S, Walker ID, et al. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/53\">",
"      Lockwood C, Wendel G, Committee on Practice Bulletins&mdash; Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/54\">",
"      Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/55\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk (Green-top 37a) file://www.rcog.org.uk/womens-health/clinical-guidance/reducing-risk-of-thrombosis-greentop37a (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/57\">",
"      Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/58\">",
"      Girling JC, de Swiet M. Thromboembolism in pregnancy: an overview. Curr Opin Obstet Gynecol 1996; 8:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/59\">",
"      Paidas MJ, Ku DH, Lee MJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/60\">",
"      Lijfering WM, Mulder R, ten Kate MK, et al. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 2009; 113:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/61\">",
"      Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/62\">",
"      B&oslash;naa KH, Nj&oslash;lstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/63\">",
"      Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/64\">",
"      den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/65\">",
"      van der Meer FJ, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/66\">",
"      Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/67\">",
"      Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002; 32:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/68\">",
"      Brattstr&ouml;m L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/69\">",
"      Ren A, Wang J. Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis. Fertil Steril 2006; 86:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/70\">",
"      Simioni P, Tormene D, Prandoni P, Girolami A. Pregnancy-related recurrent events in thrombophilic women with previous venous thromboembolism. Thromb Haemost 2001; 86:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/71\">",
"      Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/72\">",
"      Warren JE, Simonsen SE, Branch DW, et al. Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias. Am J Obstet Gynecol 2009; 200:281.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Thromboembolism in pregnancy. ACOG practice bulletin #19. American College of Obstetricians and Gynecologists, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Anticoagulation with low-molecular-weight heparin during pregnancy. ACOG Committee Opinion #211. ACOG 1998; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/75\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol 2002; 100:845.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. Thromboprophylaxis during pregnancy, labour and after vaginal delivery/ Guideline #37. January 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/77\">",
"      Bowles L, Cohen H. Inherited thrombophilias and anticoagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/78\">",
"      Sephton V, Farquharson RG, Topping J, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/79\">",
"      Gyamfi C, Cohen R, Desancho MT, Gaddipati S. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern Fetal Neonatal Med 2005; 18:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/80\">",
"      Fox NS, Laughon SK, Bender SD, et al. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008; 112:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/81\">",
"      Roeters van Lennep JE, Meijer E, Klumper FJ, et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost 2011; 9:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/82\">",
"      Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/83\">",
"      Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/84\">",
"      Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010; 30:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/85\">",
"      Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/86\">",
"      Gris JC, Mercier E, Qu&eacute;r&eacute; I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103:3695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/87\">",
"      Folkeringa N, Brouwer JL, Korteweg FJ, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/88\">",
"      Badawy AM, Khiary M, Sherif LS, et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 2008; 28:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/89\">",
"      Dolitzky M, Inbal A, Segal Y, et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/90\">",
"      Fawzy M, Shokeir T, El-Tatongy M, et al. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008; 278:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/91\">",
"      Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/92\">",
"      Abou-Nassar K, Kovacs MJ, Kahn SR, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/93\">",
"      Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost 2010; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/94\">",
"      Younis JS, Ohel G, Brenner B, et al. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000; 107:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/95\">",
"      Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/96\">",
"      Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/97\">",
"      Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/5/26714/abstract/98\">",
"      Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115:4162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4792 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26714=[""].join("\n");
var outline_f26_5_26714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7898475\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898243\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898251\">",
"      Types of inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898258\">",
"      PURPORTED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898272\">",
"      Maternal venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898279\">",
"      Obstetrical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898286\">",
"      - Spontaneous abortion, fetal loss and stillbirth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898294\">",
"      - Fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898301\">",
"      - Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898309\">",
"      - Abruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898317\">",
"      Fetal thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898324\">",
"      SELECTION OF PATIENTS FOR TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898332\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898340\">",
"      When to test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898348\">",
"      Test panel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898355\">",
"      PREVENTION OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898363\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35472870\">",
"      - Women with high-risk thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35472877\">",
"      Women with lower-risk thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898370\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898424\">",
"      - Stage of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20962219\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20962227\">",
"      Intrapartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20962235\">",
"      Postpartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898432\">",
"      - Dose and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27471887\">",
"      Therapeutic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27471903\">",
"      Prophylactic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27471911\">",
"      Intermediate dose anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898454\">",
"      - Risk of bleeding and reversal of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898461\">",
"      MATERNAL SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898468\">",
"      PREVENTION OF PREGNANCY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20962302\">",
"      Fetal surveillance and timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898475\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7898483\">",
"      Prevention of VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/49/23325\" title=\"table 1\">",
"      VTE risk in pregnancy by thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/35/40508\" title=\"table 2\">",
"      Anticoagulation regimens in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/8/19597\" title=\"table 3\">",
"      Thromboprophylaxis recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_5_26715="Iron bioavailability";
var content_f26_5_26715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors influencing the absorption and bioavailability of dietary iron",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absorption of heme iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amount of heme iron, especially in meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Content of calcium in the meal (calcium impairs iron absorption)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absorption of nonheme iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amount of potentially available nonheme iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Balance between positive and negative factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Positive factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ascorbic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Meat or fish (heme iron enhances absorption of nonheme iron)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Negative factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Phytate (in bran, oats, rye fiber)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Polyphenols (in tea, some vegetables and cereals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dietary calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Soy protein",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hallberg L, Rossander-Hulten L, Burne M. Nutritional anemias. In: Nestle Workshop Series, vol 30, Fomon SJ, Zlotkin S (Eds), Vevey/Raven Press, New York 1992. p.170.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26715=[""].join("\n");
var outline_f26_5_26715=null;
var title_f26_5_26716="Clinical features of POEMS syndrome";
var content_f26_5_26716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of POEMS syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mayo series (n = 99)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Soubrier, et al. (n = 25)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nakanishi, et al. (n = 102)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Polyneuropathy",
"        </strong>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Organomegaly",
"        </strong>",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Splenomegaly",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphadenopathy",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Endocrinopathy",
"        </strong>",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Monoclonal plasma cell disorder",
"        </strong>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Skin changes",
"        </strong>",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperpigmentation",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertrichosis",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table indicates the percent of patients from three major series of patients with POEMS who satisfied each of the original five components of this syndrome.",
"    <div class=\"footnotes\">",
"     NA: data not available.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dispenzieri, A, et al. Blood 2003; 101:2496.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26716=[""].join("\n");
var outline_f26_5_26716=null;
var title_f26_5_26717="Contents: Pulmonary disease";
var content_f26_5_26717=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pulmonary disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonary disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5818\">",
"           Diagnosis and management of asthma in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11014\">",
"           Emergency airway management in the geriatric patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/31/7671\">",
"           Sleep apnea and other causes of impaired sleep in older adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E0995E080A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_5_26717=[""].join("\n");
var outline_f26_5_26717=null;
var title_f26_5_26718="Traumatic ulcer 2";
var content_f26_5_26718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traumatic lip ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower lip ulceration from lip chewing in a 3-year-old child with Lesch-Nyhan syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26718=[""].join("\n");
var outline_f26_5_26718=null;
var title_f26_5_26719="DILI hepatotoxins";
var content_f26_5_26719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Mechanisms of drug-induced liver injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_5_26719=[""].join("\n");
var outline_f26_5_26719=null;
